Patent Grant
12310978
Described herein are methods of treatment with pharmaceutical compositions and dosage forms. Accordingly, the present disclosure generally involves health sciences, the fields of chemistry, pharmaceutical sciences, and medicine.
A particularly difficult problem in regards to orally administered lipophilic drugs is pharmacokinetic variability seen based on food effects. Many pharmaceuticals have important dosing requirements based on the effect of food on their pharmacokinetics. Some pharmaceuticals need to be taken without food. Some pharmaceuticals need to be taken with food. Other pharmaceuticals need to be taken with specific types of food. Yet other pharmaceuticals can be taken regardless of food. More complicated or specific food requirements for dosing can lead to less than desirable efficacy or safety of the pharmaceutical since; in general, a target population has quite variable eating habits. For instance, certain people are vegetarians, certain people may not eat breakfast, certain people may have a low-fat diet, certain people may have a high-fat diet, and certain people have highly variable diets with respect to fat content. These variables are difficult to control in a real world setting. Studies with Andriol Testocaps®, a testosterone undecanoate containing oral product, have shown that meal fat content has substantial effects on the bioavailability of serum testosterone. Schnabel et al., Clinical Endocrinology (2007) 66, 579-585. Similarly, another testosterone undecanoate oral formulation being developed by Clams Therapeutics exhibits non-bioequivalency as a function of meal fat content. See Yin et al. J Androl. 2012 November-December; 33(6): 1282-1290).
Thus, the present inventors recognize a need for oral formulations with testosterone undecanoate bioavailability that is not substantially altered by meal fat content.
The present disclosure is related to formulations and methods of orally administering formulations containing a lipophilic drug such as testosterone undecanoate (“TU”) or other testosterone esters.
The present inventors have surprisingly discovered oral testosterone undecanoate compositions that can be effectively administered to hypogonadal males with a meal without the fat content of the meal substantially effecting bioavailability. This result is unexpected and in direct contrast to the bioavailability performance reported for many other testosterone undecanoate oral formulations, which conclude that bioavailability is affected by meal fat content.
Upon receipt of the information in this disclosure, the ordinarily skilled artisan will be able to recognize oral testosterone undecanoate formulations that are bioequivalent to the formulations disclosed herein, including formulations that are bioequivalent for Cmax, AUC(0-t), AUC(0-∞), Cavg, or a combination thereof at low, standard, and high fat conditions as well as standard versus low fat, standard versus high fat and low versus high fat for serum testosterone, testosterone undecanoate, dihydrotestosterone, dihydrotestosterone undecanoate, or a combination thereof. Pharmaceutically equivalent formulations are also provided.
In view of the results described herein, a pharmaceutical composition is provided that is bioequivalent for serum testosterone, testosterone undecanoate, dihydrotestosterone, dihydrotestosterone undecanoate or a combination thereof for Cmax, AUC(0-t), AUC(0-∞), Cavg, or a combination thereof for a standard meal versus either a low fat or high fat meal; for low, standard, and high fat meals; for low versus high fat. The pharmaceutical compositions or dosage forms can also be pharmaceutically equivalent.
Described herein are pharmaceutical compositions that are bioequivalent for serum testosterone levels to a formulation having 50 mg to 350 mg testosterone undecanoate (e.g., in one aspect either 75 mg or 112.5 mg TU) at about 15 wt % loading, about 63 wt % Maisine 35-1, about 16 wt % Cremophor RH 40 and about 6 wt % PEG 8000. The bioequivalent composition typically has from 10 wt %-50 wt % testosterone undecanoate and 50 wt %-90 wt % pharmaceutically acceptable carrier. The bioequivalent compositions are bioequivalent for serum testosterone undecanoate, dihydrotestosterone, dihydrotestosterone undecanoate, or a combination thereof for Cmax, AUC(0-t), AUC(0-∞), Cavg, or a combination thereof at low, standard, and high fat conditions as well as standard versus low fat, standard versus high fat and low versus high fat. Any carrier can be used so long as the compositions are bioequivalent to the formulation having 50 mg to 350 mg testosterone undecanoate (e.g., in one aspect either 75 mg or 112.5 mg TU) at about 15 wt % loading, about 63 wt % Maisine 35-1, about 16 wt % Cremophor RH 40 and about 6 wt % PEG 8000. In some aspects, the formulation is also pharmaceutically equivalent to that described herein.
Also provided herein are methods for replacement therapy in a male for conditions associated with a deficiency or absence of endogenous testosterone. The methods involve orally administering a pharmaceutical composition having TU and a pharmaceutically acceptable carrier with a meal. The meal can be any meal regardless of fat content, the meal can also be a low fat meal, a standard fat meal, or a high fat meal. The methods provide bioequivalent Cmax, AUC(0-t), AUC(0-∞), Cavg, or a combination thereof, when administered with any of low fat, standard fat, or high fat meals. Alternatively, the methods provide bioequivalent Cmax, AUC(0-t), AUC(0-∞), Cavg, or a combination thereof, when administered with a standard fat meal as compared to low or high fat meals. In another alternative, the method provides bioequivalent Cmax, AUC(0-t), AUC(0-∞), Cavg, or a combination thereof when administered with a low fat meal as compared to a high fat meal. When the composition is administered with a TU total daily dose range of about 275 mg (e.g., 300 mg) to about 625 mg (e.g., 600 mg), the composition provides a serum testosterone Cavg at steady state in the range of 300 ng/dL to about 1100 ng/dL to a subject in need of treatment. The methods can include a dose titration as described herein.
Thus, the results described herein support a drug label indicating (or method involving) that the oral testosterone replacement therapy (testosterone undecanoate containing oral dosage form) is taken (1) “WITH A MEAL” or (2) “WITH MEAL, BUT NOT ON EMPTY STOMACH” or (3) “WITH FAT CONTAINING FOOD” not specifying fat content. In an alternative, the drug label may indicate (or method may involve) the oral testosterone replacement therapy (testosterone undecanoate containing oral dosage form) is taken “WITH MEAL, BUT NOT LOW FAT”. In an alternative, the drug label may indicate (or method may involve) the oral testosterone replacement therapy (testosterone undecanoate containing oral dosage form) is taken “WITH MEAL, BUT NOT HIGH FAT”. In an alternative, the drug label may indicate (or method may involve) the oral testosterone replacement therapy (testosterone undecanoate containing oral dosage form) is taken “WITH STANDARD OR NORMAL MEAL”.
Before the present testosterone undecanoate compositions, oral dosage forms, such as capsules, and related methods of use are disclosed and described in more detail and variations, it is to be understood that this invention is not limited to the particular process steps and materials disclosed herein, but is extended to equivalents thereof, as would be recognized by those ordinarily skilled in the relevant arts. It should also be understood that terminology employed herein is used for the purpose of describing particular embodiments only and is not intended to be limiting.
In specific embodiments, provided herein are the following:
It should be noted that as used in this written description, the singular forms “a,” “an,” and, “the” include express support for plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “an excipient” includes support for one or more of such excipients, and reference to “the carrier” includes support for one or more of such carriers.
As used herein, “pharmaceutically equivalent”, refers to a composition or unit dosage form drug product if they meet three criteria: they contain the same active ingredient(s); they are of the same dosage form and route of administration; they are identical in strength or concentration. Typically, pharmaceutical equivalent drug products may differ in characteristics such as shape, release mechanism, labeling (to some extent), scoring and excipients (including colors, flavors, preservatives) although this list in not-limiting.
As used herein, “bioequivalent”, refers to the absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same dose under similar conditions in an appropriately designed study. Two products are bioequivalent if the 90% CI (Confidence Interval) of the relative mean Cmax, AUC(0-t) and AUC(0-∞) of the test (e.g., generic formulation) to reference (e.g., innovator brand formulation) should be within 70% to 143% and preferably 80.00% to 125.00% under particular conditions e.g., fed, fasted, particular fat content in meals (e.g., low, standard, or high). Unless otherwise specified, bioequivalence can be for serum testosterone undecanoate, serum testosterone, serum dihydrotestosterone or serum dihydrotestosterone undecanoate. Typically, bioequivalence is determined with a group of subjects.
As used herein, the term “treatment,” when used in conjunction with the administration of pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, refers to the administration of the oral dosage capsules and pharmaceutically acceptable composition to subjects who are either asymptomatic or symptomatic. In other words, “treatment” can both be to reduce or eliminate symptoms associated with a condition present in a subject, or it can be prophylactic treatment, i.e., to prevent the occurrence of the symptoms in a subject. Such prophylactic treatment can also be referred to as prevention of the condition.
As used herein, the terms “formulation” and “composition” are used interchangeably and refer to a mixture of two or more compounds, elements, or molecules. In some aspects the terms “formulation” and “composition” may be used to refer to a mixture of one or more active agents with a carrier or other excipients. Furthermore, the term “dosage form” can include one or more formulation(s) or composition(s) provided in a format for administration to a subject. When any of the above terms is modified by the term “oral” such terms refer to compositions, formulations, or dosage forms formulated and intended for oral administration to subjects.
As used herein, the term “fatty acid” refers to unionized carboxylic acids with a long aliphatic tail (chain), either saturated or unsaturated, conjugated or non-conjugated. Typically, the fatty acid is a C8 to C22 fatty acid.
Unless otherwise specified, the term C8 to C22 fatty acid glycerides refers to a mixture of mono-, di-, and/or tri-glycerol esters of medium to long chain (C8 to C22) fatty acids.
As used herein, the term “solidifying agent” or “solidifying additive” are used interchangeably and refer to a pharmaceutically acceptable additive that is in a solid physical state at 20° C. Similarly, a “solid lipophilic additive” refers to a lipophilic compound or component that is in a solid physical state at 20° C. and/or renders the composition or dosage form non-liquid, such as solid or semi-solid.
As used herein, the term “lipophilic,” refers to compounds that are not freely soluble in water; and the term “lipophilic surfactant” refers to surfactants that have HLB values of about 10 or less. Conversely, the term “hydrophilic” refers to compounds that are soluble in water; and term “hydrophilic surfactant” refers to surfactants that have HLB values of more than about 10.
As used herein, the term “ionizable fatty acid” refers to a fatty acid compound that changes its HLB as a function of pH. For example, oleic acid is predominantly lipophilic at lower pH values (such as those found in the stomach) but becomes a predominantly hydrophilic at higher pH values (such as those found in the intestine).
As used herein, “subject” refers to a mammal that may benefit from the administration of a drug composition or method of this invention. Examples of subjects include humans. In one aspect, the subject can be a human male. In another embodiment, the subject can be a hypogonadal male. In one aspect, the subject is a male in need of replacement therapy for conditions associated with a deficiency or absence of endogenous testosterone. As used herein, the testosterone deficiency or hypogonadism in a male human subject (hypogonadal male) refers to a condition wherein the average baseline plasma testosterone concentration (T-Cavg-B) is about 300 ng/dL or less. However, in some instances, testosterone deficiency or hypogonadism in a male human subject refers to a condition wherein the average baseline plasma testosterone concentration is about 400 ng/dL or less.
As used herein, “group” or “group of subjects” refers to a collection of at least 12 human male subjects who receive and respond to exogenous oral administration of the compositions disclosed herein, namely testosterone undecanoate-containing compositions. In one aspect, the group can include at least 100 or at least 300 male subjects. In another aspect, the group can include at least 1000 male subjects. In another embodiment, the subjects can be hypogonadal subjects.
The term “oral administration” represents any method of administration in which an active agent can be administered by swallowing, chewing, or sucking of the dosage form. The composition of the current inventions can be admixed with food or drink prior to being orally consumed.
As used herein, a “dosing regimen” or “regimen” such as an “initial dosing regimen” or a “maintenance dosing regimen” refers to how, when, how much, and for how long a dose of the compositions of the present invention can be administered to a subject. For example, an initial dosing regimen for a hypogonadal male subject may provide for a total daily dose of 450 mg administered in two divided doses at about 12 hours apart (e.g., once with breakfast and once with dinner) with meals (e.g., having about 10 g to 55 g of fat content, or any other appropriate meal) repeated daily for at least one week, two weeks or 30 days.
As used herein, “daily dose” refers to the amount of active agent (e.g., testosterone undecanoate) administered to a subject over a 24-hour period of time (e.g., per day). The daily dose can be administered as one or two or more administrations during the 24 hour period (twice-a-day). In one embodiment, the daily dose provides for two administrations in a 24 hour period. With this in mind, an “initial dose” or initial daily dose” refers to a dose administered during the initial regimen or period of a dosing regimen. An initial dose includes both the very first dose during the initial regimen as well as the subsequent doses during the same initial regimen. Similarly, a “maintenance dose” or “maintenance daily dose” refers to a dose administered during a maintenance regimen of a dosing regimen. It is worth noting that the maintenance dose follows a dose titration based on the serum testosterone determination on a titration node day (after a single dose of the initial daily dose at steady state), however the maintenance dose does not need to be of a different quantity as the initial dose or the previous maintenance dose (in the case of multiple titrations).
As used herein, the term “solidifying agent” or “solidifying additive” are used interchangeably and refer to a pharmaceutically acceptable additive that is in a solid physical state at 20° C. Similarly, a “solid lipophilic additive” refers to a lipophilic compound or component that is in a solid physical state at 20° C. and/or renders the composition or dosage form non-liquid, such as solid or semi-solid.
As used herein, “non-liquid” when used to refer to the state of a composition disclosed herein refers to the physical state of the composition as being a semi-solid or solid.
As used herein, “solid” and “semi-solid” refers to the physical state of a composition that supports its own weight at standard temperature and pressure, and has adequate viscosity or structure to not freely flow. Semi-solid materials may conform to the shape of a container under applied pressure.
As used herein, “titration” or “dose titration” or “dose adjustment” are used interchangeably and refer to an increase or decrease of the total daily dose of testosterone undecanoate administered to a subject, typically based on the response of the subject to the exogenous administered testosterone undecanoate. The dose can be increased or decreased based on the measurement of serum testosterone concentration after a steady state has been achieved.
As used herein, “steady state” refers to the achievement of a stable response in serum total testosterone levels to exogenously administered testosterone undecanoate, typically achieved after at least 15 days following the start of a dosing regimen.
As used herein, “initial daily dose” (IDD) or “Daily dose of the initial regimen” is a dose of testosterone undecanoate administered daily to a subject in need of testosterone therapy. The initial daily dose may be administered in one or two or more intervals over a 24-hour period, e.g., twice-a-day. Similarly, “maintenance daily dose” or “daily dose of the maintenance regimen” is a dose of testosterone undecanoate administered daily to a subject in need of testosterone therapy as determined based on measurement of the titration node day titration metric and is the daily dose going forward within a few days of measurement unless a dose change is needed based on a another titration node day measurement. During a maintenance regimen there may be one or two or more daily doses administered which at some point during the regime would be considered to be the maintenance daily dose.
As used herein, “titration node” or “titration node day” are used interchangeably and refer to a day on which a serum sample is drawn from a subject for measurement of the serum testosterone concentrations in order to determine whether a testosterone undecanoate dose titration is necessary and what the titration type might need to be. The measured serum testosterone levels may also be used to determine dose a titration metric to be utilized in deciding dose titration needs for an individual subject. As dosing regimens can include one or more titration node day the term may refer to a first titration node during a dosing regimen (e.g., between the initial dosing regimen and the maintenance dosing regimen) or it can refer to a subsequent titration node day between a maintenance dosing regimen and a subsequent maintenance dosing regimen.
As used herein, the terms “release” and “release rate” are used interchangeably to refer to the discharge or liberation of a substance, including without limitation a drug, from the dosage form into a surrounding environment such as an aqueous medium either in vitro or in vivo.
As used herein, an “effective amount” or a “therapeutically effective amount” of a drug refers to a non-toxic, but sufficient amount of the drug, to achieve therapeutic results in treating a condition for which the drug is known to be effective. It is understood that various biological factors may affect the ability of a substance to perform its intended task. Therefore, an “effective amount” or a “therapeutically effective amount” may be dependent in some instances on such biological factors. Further, while the achievement of therapeutic effects may be measured by a physician or other qualified medical personnel using evaluations known in the art, it is recognized that individual variation and response to treatments may make the achievement of therapeutic effects a somewhat subjective decision. The determination of an effective amount is well within the ordinary skill in the art of pharmaceutical sciences and medicine. See, for example, Meiner and Tonascia, “Clinical Trials: Design, Conduct, and Analysis,” Monographs in Epidemiology and Biostatistics, Vol. 8 (1986), incorporated herein by reference.
The terms “plasma testosterone concentration,” “testosterone concentration in the blood,” and “serum testosterone concentration” are used interchangeably and refer to the “total” testosterone concentration which is the sum of the bioavailable testosterone including free and protein-bound testosterone concentrations. As with any bio-analytical measure, for increased consistency the method employed to measure initial serum testosterone levels should be consistent with the method used to monitor and re-measure serum testosterone levels during clinical testing and testosterone therapy for a subject. Likewise, serum or plasma (used interchangeably) testosterone undecanoate and the metabolites dihydrotestosterone and dihydrotestosterone undecanoate, can be determined by the ordinary skilled artisan.
As used herein, of the average serum testosterone concentration can be determined using methods and practices known in the art. For example, the average baseline plasma testosterone concentration of a human male is the arithmetic mean of the total plasma testosterone concentrations determined on at least two consecutive time points that are reasonably spaced from each other, for example from about 1 hour to about 168 hours apart. In a particular case, the plasma testosterone concentration can be determined on at least two consecutive times that are about 12 hours to about 48 hours apart. In another particular method, the plasma testosterone concentration of the human male can be determined at a time between about 5 am and about 11 am. Further, the plasma testosterone concentration can be the determined by standard analytical procedures and methods available in the art, such as for example, automated or manual immunoassay methods, liquid chromatography or liquid chromatography-tandem mass spectrometry (LC-MSMS) etc.
As used herein, the term AUC0-t is the area under the curve of a plasma-versus-time graph determined for the analyte from the time 0 to time “t”.
As used herein, the term “Cavg,” “Cave,” or “C-average” are used interchangeably, and is determined as the AUC0-t or the mean AUC divided by the time period (t). For example, Cavg-8 h is the average plasma concentration over a period of 8 hours post-dosing determined by dividing the AUC0-8 value by 8. Similarly, Cavg-12 h is the average plasma concentration over a period of 12 hours post-dosing determined by dividing the AUC0-12 value by 12; Cavg-24 h is the average plasma concentration over a period of 24 hours post-dosing determined by dividing the AUC0-24 h value by 24, and so on. Unless otherwise stated, all Cave values are considered to be Cave-24 h.
As used herein “Cmax” refers to the maximum measured serum concentration of the administered drug or a metabolite after single dose administration.
As used herein, “free of” or “substantially free of” of a particular compound or compositions refers to the absence of any separately added portion of the referenced compound or composition. Free of or substantially free of can include the presence of 1 wt % or less (based on total composition weight) of the referenced compound which may be present as a component or impurity of one or more of the ingredients.
As used herein, the term “TU” refers to testosterone undecanoate.
As used herein, “with a meal” generally means within an hour of a meal (e.g., plus/minus an hour or preferably within 30 minutes). More preferably, “with a meal” means within 30 minutes of a meal e.g., within 30 minutes after the subject has eaten a meal. Even more preferably, “with a meal” refers to about 30 minutes after the subject has eaten a meal.
As used herein, the terms “meal” and “food” can be used interchangeably.
As used herein, “low fat” or “low fat meal” generally refers a meal having less than about 30 grams of fat. For example, in some cases, “low fat” or “low fat meal” refers to a meal having from about 10 grams to about 30 grams of fat, or about 10 grams to about 25 grams of fat, or about 15 grams to about 25 grams of fat, or about 15 grams of fat.
As used herein, “medium fat,” “medium fat meal,” “standard fat,” “standard meal,” or “standard fat meal” generally refers to a meal having from about 20 grams of fat to about 50 grams of fat. For example, in some cases, “medium fat,” “medium fat meal,” “standard fat,” “standard meal,” or “standard fat meal” refer to a meal having from about 20 grams to about 45 grams of fat, about 20 grams to about 40 grams of fat, about 25 grams to about 35 grams of fat, or about 30 grams of fat.
As used herein, “high fat” or “high fat meal” generally refers to a meal having 40 or more grams of fat. For example, in some cases, “high fat” or “high fat meal” can refer to a meal having from about 40 to about 100 grams of fat, about 45 grams to about 100 grams of fat, about 45 grams to about 90 grams of fat, about 45 to about 75 grams of fat, about 45 grams to about 60 grams of fat, or about 50 grams. Further, in some other examples, “high fat meal” can be a meal having greater than 45 grams of fat or a meal having greater than 50 grams of fat.
As used herein, the term “about” is used to provide flexibility to a numerical range endpoint by providing that a given value may be “a little above” or “a little below” the endpoint. As used herein, a plurality of items, structural elements, compositional elements, and/or materials may be presented in a common list for convenience. However, these lists should be construed as though each member of the list is individually identified as a separate and unique member. Thus, no individual member of such list should be construed as a de facto equivalent of any other member of the same list solely based on their presentation in a common group without indications to the contrary.
As used herein, a plurality of items, structural elements, compositional elements, and/or materials may be presented in a common list for convenience. However, these lists should be construed as though each member of the list is individually identified as a separate and unique member. Thus, no individual member of such list should be construed as a de facto equivalent of any other member of the same list solely based on their presentation in a common group without indications to the contrary.
Concentrations, amounts, levels and other numerical data may be expressed or presented herein in a range format. It is to be understood that such a range format is used merely for convenience and brevity and thus should be interpreted flexibly to include not only the numerical values explicitly recited as the limits of the range, but also to include all the individual numerical values or sub-ranges or decimal units encompassed within that range as if each numerical value and sub-range is explicitly recited. As an illustration, a numerical range of “about 1 to about 5” should be interpreted to include not only the explicitly recited values of about 1 to about 5, but also include individual values and sub-ranges within the indicated range. Thus, included in this numerical range are individual values such as 2, 3, and 4 and sub-ranges such as from 1-3, from 2-4, and from 3-5, etc., as well as 1, 2, 3, 4, and 5, individually. This same principle applies to ranges reciting only one numerical value as a minimum or a maximum. Furthermore, such an interpretation should apply regardless of the breadth of the range or the characteristics being described.
Described herein are formulations and methods of using those formulations for testosterone replacement therapy. The formulations described herein are for oral administration for replacement therapy in a male for conditions associated with a deficiency or absence of endogenous testosterone (e.g., a hypogonadal male or a male experiencing a symptom of testosterone deficiency). In some aspects, the therapy can be used in females.
It is noted that testosterone deficiency can typically be associated with a variety of conditions, each of which can cause or contribute to the deficiency or absence of testosterone in a subject. The compositions and oral dosage capsules of the present invention can be used to treat any condition associated with testosterone deficiency, including complete absence, of endogenous testosterone. Examples of conditions associated with testosterone deficiency that can be treated using the oral dosage capsules and/or compositions of the present invention include, but are not limited to congenital or acquired primary hypogonadism, hypogonadotropic hypogonadism, cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchidectomy, Klinefelter's syndrome, post castration, eunuchoidism, hypopituitarism, endocrine impotence, infertility due to spermatogenic disorders, impotence, male sexual dysfunction (MSD) including conditions such as premature ejaculation, erectile dysfunction, decreased libido, and the like, micropenis and constitutional delay, penile enlargement, appetite stimulation, testosterone deficiency associated with chemotherapy, testosterone deficiency associated with toxic damage from alcohol, heavy metal, or other substances, osteoporosis associated with androgen deficiency, late-onset hypogonadism (e.g., age-related), or combinations thereof.
Additionally, the compositions and oral dosage forms disclosed herein include can also be used to treat idiopathic gonadotropin, LHRH deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. Typically, these subjects have low serum testosterone levels but have gonadotropins in the normal or low range. In one embodiment, the compositions or oral dosage forms can be used to stimulate puberty in carefully selected males with clearly delayed puberty not secondary to pathological disorder. In another embodiment, the compositions and oral dosage forms can be used in female-to-male transsexuals in order to maintain or restore male physical and sexual characteristics including body muscle mass, muscle tone, bone density, body mass index (BMI), enhanced energy, motivation and endurance, restoring psychosexual activity, etc. In some embodiments, the testosterone undecanoate compositions and oral dosage capsules can be useful in providing hormonal male contraception.
Additionally, testosterone therapy can also be used to improve the quality of life of subjects suffering from conditions such as decreased libido, diminishing memory, anemia due to marrow failure, renal failure, chronic respiratory or cardiac failure, steroid-dependent autoimmune disease, muscle wasting associated with various diseases such as AIDS, preventing attacks of hereditary angioedema or urticaria; andropause, and palliating terminal breast cancer. In some situations, certain biomarkers such as for example, increased SHBG levels, can be used to diagnose a subject who may be in need of testosterone therapy. These biomarkers can be associated with conditions/disease states such as anorexia nervosa, hyperthyroidism, hypogonadism, androgen insensitivity/deficiency, alcoholic hepatic cirrhosis, primary biliary cirrhosis, and the like.”
In one specific embodiment, formulations and oral dosage forms as described herein can be used to treat primary hypogonadism (congenital or acquired) or hypogonadotropic hypogonadism (congenital or acquired).
The formulations can be any formulation having a testosterone ester e.g., testosterone undecanoate and one or more carriers. The carriers are selected such that the formulation, when administered orally for replacement therapy in a male for conditions associated with a deficiency or absence of endogenous testosterone, produces bioequivalent serum testosterone levels when administered with low, standard, or high fat meals. Bioequivalence can be determined by an ordinary skilled artisan in view of Examples described herein. The carriers and amounts thereof are selected such that the formulation provides bioequivalent levels of serum testosterone when administered under high fat meals versus low fat meals, standard meals versus low fat meals, standard meals versus high fat meals, or low, standard, or high fat meals.
In one embodiment, the composition or oral dosage form can be administered with a meal, such as a meal that provides about 200 calories to about 1000 calories of food energy. In another embodiment, the composition or oral dosage form can be administered with a meal that provides about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 70%, 80%, 90% or 100% of the calories from the fat (or within a range derived from any combination of these values). In yet another embodiment, the composition or oral dosage form can be administered with a meal that provides about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% of the calories from the fat (or within a range derived from any combination of these values). In yet another embodiment, the composition of oral dosage form can be administered with a meal that provides about 10% to about 50% of the calories from the fat. In one aspect, where about 10% to about 50% of the calories are from the fat, the meal can include at least 10 grams or at least 15 grams of fat. In another embodiment, the composition or oral dosage form can be administered with a high-fat, high calorie meal. In another embodiment, the composition or oral dosage form can be administered with a standard meal that provides about 500 calories to about 1000 calories of energy. The compositional make-up of the meals that are administered can vary depending on the tastes and dietary needs of a subject. However, in some situations it may be beneficial to administer the compositions and oral dosage forms with meals that provide no fat to about 100 g of fat. In one embodiment, the meal can provide about 10 g to about 50 g of fat. In yet a further embodiment, the meal can provide 15 g to about 35 g of fat. In yet a further embodiment, the meal can provide about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 grams of fat (or within a range derived from any combination of these values).
It is noted that any type of food or meal can be used in the methods and with the compositions described herein depending on the particular embodiment or aspect of the invention. Typically, the amount of fat or calories per serving is available on the food label or otherwise provided, such as by a restaurant. Fat content or calories in food and meals can also be determined or estimated by an individual using the methods and compositions disclosed herein by consulting typical books on nutrition or nutritional databases such as those provided by the USDA (United States Department of Argiculture) which are available online.
Exemplary, breakfasts and foods with ≥15 g fat are given below, as provided by the USDA Nutrient Database (each of which can be modified to achieve a desired fat content, calorie content, or combination thereof, and are not intended to be limiting examples). The fat and calorie content of food or dinner meals can be similarly determined by consulting label information, online information and databases, nutrition books, information provided by restaurants, and the like.
1 cup toasted wheat germ cereal (12 g)+1 cup lowfat (2%) milk (5 g): 17 g fat
1 slice whole wheat toast (1 g)+2 Tablespoons peanut butter (16 g): 17 g fat
1 small bagel (1.5 g)+1.5 oz cream cheese (15 g): 16.5 g fat
½ cup homemade granola cereal (15 g): 15 g fat
2 boiled eggs (10 g)+1 oz turkey bacon (5 g): 15 g fat
2 boiled eggs (10 g)+1 slice whole wheat toast (1 g)+1 teaspoon butter (4 g): 15 g fat
1 medium butter croissant (12 g)+coffee with 1 Tablespoon cream (3 g): 15 g fat
¼ cup almonds, whole: 18 g fat
¼ cup sunflower seeds: 18 g fat
2 oz cheddar cheese: 18 g fat
Other non-limiting examples of foods or meals that a subject can have with the compositions and methods disclosed herein can include, for example:
Mega Melt with Reg eggs, 6″ sandwich, hash browns, 12 fl oz orange juice: 36 g fat (1014 kcal)
6″ Subway Melt Omelet Sandwich with regular egg, hash browns, 12 fl oz orange juice: 37 g fat (1074 kcal)
6″ sausage, eggs & cheese omelet sandwich, hash browns, 12 fl oz orange juice: 29 g fat (854 kcal)
Bacon, egg & cheese on 3″ flatbread, hash brown, 12 fl oz orange juice: 28 g fat (814 kcal)
McDonalds hotcakes with sausage, syrup, hash browns: 33 g fat (850 kcal);
Fruit & maple oatmeal, hash browns, egg McMuffin, nonfat Latte: 34 g fat (980 kcal)
Panera cinnamon roll and strawberry granola parfait: 35 g fat (940 kcal)
Starbuck's bacon and gouda Artisan breakfast sandwich, steel cut oatmeal with blueberry topping, and greek yogurt with berries parfait: 31 g fat (920 kcal)
As will be recognized by one skilled in the art, there are numerous other food or meal options that can be used to arrive at a low, medium, or high fat meal.
Whether or not the compositions or oral dosage forms described herein are administered with a meal, the compositions and oral dosage forms can be used in a variety of regimens for testosterone replacement therapy and other treatments or therapies. For example, in one embodiment, a testosterone replacement therapy for twice daily oral dosing is provided comprising: (a) 2 (or 3) different dose strength oral dosage forms having different amounts of testosterone undecanoate; (b) 3 dosing regimens providing for 3 different daily doses of testosterone undecanoate; (c) both (a) and (b); or (d) a pharmaceutically equivalent version thereof. In one aspect, the testosterone replacement therapy provides steady state serum levels of testosterone (Cavg) to a male having testosterone deficiency or in need of said therapy in the range of about 300 ng/dL to about 1140 ng/dL. In one aspect, the testosterone replacement therapy provides steady state serum levels of testosterone (Cavg) to a male having testosterone deficiency or in need of said therapy in the range of about 400 ng/dL or 435 ng/dL to about 1140 ng/dL. In one aspect, the testosterone replacement therapy provides single dose Cmax levels of serum testosterone at steady state to a population of males (e.g., more than 30, 40, 50, 75, 100, 150 or 200 males) having testosterone deficiency, or in need of said therapy, of less than 2500 ng/dL in at least 95% of the population of males, less than 1500 ng/dL in at least 85% of the population of males; or a serum testosterone Cmax of about 1800 ng/dL to about 2500 ng/dL in 10% or less of the population of males having testosterone deficiency. In one aspect, the testosterone replacement therapy has one of the dosage forms having from about 140 to 160 mg testosterone undecanoate and the other dosage form has from about 215 mg to about 250 mg testosterone undecanoate. In one aspect, the testosterone replacement therapy can include a third dose strength that has from about 280 mg to about 320 mg of testosterone undecanoate. In one specific aspect, the third dose strength has about 300 mg testosterone undecanoate. In one aspect, the testosterone replacement therapy has one of the dosage forms having from about 145 to 155 mg testosterone undecanoate and the other dosage form has from about 220 mg to about 230 mg testosterone undecanoate. In one aspect, the testosterone replacement therapy has one the of dosage forms having about 150 mg testosterone undecanoate and the other dosage form has about 225 mg testosterone undecanoate. In one aspect, the testosterone replacement therapy has one the of dosage forms having from about 60 to 90 mg testosterone undecanoate and the other dosage form has from about 100 mg to about 130 mg testosterone undecanoate. In one aspect, the testosterone replacement therapy has one of the dosage forms having from about 70 to 80 mg testosterone undecanoate and the other dosage form has from about 107 mg to about 118 mg testosterone undecanoate. In one aspect, the testosterone replacement therapy has one of dosage forms having about 75 mg testosterone undecanoate and the other dosage form has about 112.5 mg testosterone. In one aspect, the testosterone replacement therapy has 3 dosing regimens providing for 3 different daily doses of testosterone undecanoate provide for a first daily dose of about 275 mg to about 325 mg of testosterone undecanoate, a second daily dose of from about 425 mg to about 490 mg of testosterone undecanoate and a third daily dose of about 575 mg to about 625 mg of testosterone undecanoate. In one aspect, the testosterone replacement therapy provides for 3 different daily doses of testosterone undecanoate—providing for a first daily dose of about 300 mg of testosterone undecanoate, a second daily dose of about 450 testosterone undecanoate and a third daily dose of about 600 mg of testosterone undecanoate. In one aspect, the testosterone replacement therapy comprises: 2 dosage forms, one having about 75 mg of testosterone undecanoate and the other dosage form having about 112.5 testosterone undecanoate; 3 dosing regimens, a first dosing regimen comprising administration of two dosage forms twice a day, each dosage form having about 75 mg testosterone undecanoate, a second dosing regimen comprising administration of two dosage forms twice a day each dosage form having about 112.5 mg testosterone undecanoate, and a third dosing regimen comprising administration of four dosage forms twice a day each dosage form having about 75 mg testosterone undecanoate or a pharmaceutically equivalent version thereof. In one aspect, the testosterone replacement therapy comprises: 2 dosage forms, one having about 150 mg of testosterone undecanoate and the other dosage form having about 225 testosterone undecanoate; 3 dosing regimens, a first dosing regimen comprising administration of one dosage form twice a day each dosage form having about 225 mg testosterone undecanoate, a second dosing regimen comprising administration of two dosage forms twice a day each dosage form having about 150 mg testosterone undecanoate, and a third dosing regimen comprising administration of two dosage forms twice a day each dosage form having about 150 mg testosterone undecanoate or a pharmaceutically equivalent version thereof. As described herein, administration refers to administration to a subject in need of testosterone replacement e.g., a hypogonadal male or a male having low testosterone levels or a symptom thereof. According to this embodiment, the dosage form can be a capsule with the fill containing at particular amount (e.g., 112.5 mg) of TU at about 15 wt % loading, 63 wt % Maisine 35-1, 16 wt % Cremophor RH 40, and 6 wt % PEG 8000 or a pharmaceutically equivalent formulation thereof, a bioequivalent formulation thereof, or a combination thereof. Thus, these results support a drug label that indicates or a method that includes that the oral testosterone replacement therapy (oral formulation) is taken (1) “WITH A MEAL” or (2) “WITH MEAL, BUT NOT ON EMPTY STOMACH” or (3) “WITH FAT CONTAINING FOOD” not specifying fat content. In an alternative aspect, the drug label may indicate or the method includes that the formulation is taken “WITH MEAL, BUT NOT LOW FAT”. In an alternative aspect, the drug label may indicate or the method includes that the formulation is taken “WITH MEAL, BUT NOT HIGH FAT”. In an alternative aspect, the drug label may indicate or the method includes that the formulation is taken “WITH STANDARD OR NORMAL MEAL”.
Accordingly, an oral dosage form can be provided in a container having a label that indicates that the oral dosage is to be taken (1) “WITH A MEAL”, (2) “WITH MEAL, BUT NOT ON EMPTY STOMACH”, (3) “WITH FAT CONTAINING FOOD” not specifying fat content, (4) “WITH MEAL, BUT NOT LOW FAT”, (5) “WITH MEAL, BUT NOT HIGH FAT”, or (6) “WITH STANDARD OR NORMAL MEAL”. Other suitable labels can also be included on the label of the container, such as those described herein. Any suitable container can be used. Non-limiting examples of suitable containers can include a bottle, a pouch, a blister package, and other similar packaging that is known in the art.
As described herein an oral TRT (testosterone replacement therapy) is provided. The TRT has three different daily doses which commence with an initial dosing regimen having a specific daily dose of testosterone undecanoate that lasts for a period of time e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 weeks. After this period of time on the initial dosing regimen, a dose titration measurement or assessment is made. The purpose of the dose titration assessment or measurement is to determine if the daily dose should remain the same as a daily dose of the initial regimen or whether the daily dose should be increased or decreased. The dose titration measurement or assessment is made by determining serum testosterone concentrations within a specific amount of time (e.g., window of time) after administration of a single dose of the initial regimen at steady state. Three options are possible based on the result of this measurement or assessment. A level of serum testosterone that is too high will result in a decrease in the total daily dose of testosterone undecanoate, a level of serum testosterone that is too low will result in an increase in the daily dose of testosterone undecanoate and intermediate levels of serum testosterone will result in no change of the daily dose of testosterone undecanoate. It was surprisingly found that the TRT described herein provides numerous benefits to individuals or populations of individuals in need of such therapy and in particular it was found that certain formulations are bioequivalent with respect to different food conditions. Thus, the oral dosage forms used in the TRT can be (1) “WITH A MEAL” or (2) “WITH MEAL, BUT NOT ON EMPTY STOMACH” or (3) “WITH FAT CONTAINING FOOD” not specifying fat content. In an alternative aspect, the drug label may indicate or the method includes that the formulation is taken “WITH MEAL, BUT NOT LOW FAT”. In an alternative aspect, the drug label may indicate or the method includes that the formulation is taken “WITH MEAL, BUT NOT HIGH FAT”. In an alternative aspect, the drug label may indicate or the method includes that the formulation is taken “WITH STANDARD OR NORMAL MEAL”. The TRT described herein provides for three different daily doses of testosterone undecanoate formulated for oral administration that are typically divided into two administrations e.g., a morning dose and an evening dose. The three daily doses of testosterone undecanoate are in the 280-320 mg range, the 430 mg to 490 mg range, and the 580 mg to 620 mg range. These daily doses are provided by two to eight unit dosage forms per day.
According to this TRT, a subject or patient e.g., hypogonadal male starts on an initial dose or initial dosing regimen that provides a specific amount of testosterone undecanoate per day for an initial period of time (e.g., greater than one, two, or three weeks) that is to be administered with food. This initial daily dose is in the range of about 430 mg to 490 mg TU per day (or 435 mg to 465 mg TU per day, 440 mg to 460 mg TU per day, 445 mg to 455 mg TU per day, or about 450 mg per day). After the initial period of time, a dose titration measurement or assessment is made. The dose titration measurement is made by determining serum testosterone levels at a specific time (e.g., within 1 to 12 hours, 1 to 11 hours, 1 to 10 hours, 1 to 9 hours, 1 to 8 hours, 1 to 7 hours, 1 to 6 hours, 1 to 5 hours, 1 to 4 hours, 2 to 10 hours, 2 to 9 hours, 2 to 8 hours, 2 to 7 hours, 2 to 6 hours, 2 to 5 hours, 2 to 4 hours, 1 to 3 hours, 2 to 3 hours, 3 to 4 hours, 4 to 5 hours, 3 to 5 hours, 4 to 6 hours, 3 to 6 hours, 3 to 8 hours, or 4 to 6 hours; or at about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 hours±0.5, 1, 1.5, or 2 hours) after a single dose of the initial regimen when the patient is at steady state. Depending of the serum testosterone level obtained from the dose titration measurement, the patient can receive a maintenance regimen that has the same daily dose as the initial regimen or the daily dose is increased or decreased. Typically, the patient or subject is then maintained on the maintenance regimen, although one or more additional dose titration measurements or dose titrations can be made. The therapy described herein is typically administered as a twice a day therapy with a meal, so a 300 mg TU dose is administered as 150 mg with a meal twice a day; a 450 mg dose is administered as 225 mg with a meal twice a day; and a 450 mg dose is administered as 225 mg with a meal twice a day.
The dose titration of the TRT described herein was found to be surprisingly robust and beneficial for patients receiving the therapy, especially in view of the food effect study described in the Examples. In a specific aspect, the up or down titration are at about 70 to 80 mg TU per dose (e.g., 75 mg TU) or about 140 to 160 mg (e.g., 150 mg TU) per day TU. Typically, the doses of TU are administered with a meal. Thus, the methods described herein can include an initial daily dose followed by a dose titration. The dose titration is used to determine the maintenance daily dose which is within plus/minus 75%, 50%, 40% or 35% of the initial daily dose.
In one embodiment, a therapy for treating a male having a baseline serum testosterone level of 300 ng/dL or less is provided, said therapy comprising: (a) 2 oral dosage forms having different amounts of testosterone undecanoate; (b) 3 dosing regimens providing different daily doses of testosterone undecanoate; (c) both (a) and (b); or (d) a pharmaceutically equivalent version thereof. In one aspect, the higher and lower daily doses are within about 40% of the intermediate dose. In one aspect, the therapy provides single dose Cmax levels of serum testosterone at steady state levels to a population of males having testosterone deficiency, or in need of said therapy, of (a) less than 2500 ng/dL in at least 95% of the population of males; (b) less than 1500 ng/dL in at least 85% of the population of males; a serum testosterone Cmax of about 1800 ng/dL to about 2500 ng/dL in 10% or less of the subjects in the group; or a combination thereof. In one aspect, a patient receiving the therapy has a dose titration assessment. In one aspect, the dose titration assessment comprises determining a value of serum testosterone at from about two to eight hours after receiving a dose of testosterone undecanoate. In one aspect, a patient having (a) a low serum testosterone level at two to eight hours after receiving a single dose of testosterone undecanoate at steady state receives a higher dose of testosterone undecanoate; (b) a high serum testosterone level at two to eight hours after receiving a single dose of testosterone undecanoate at steady state receives a lower dose of testosterone undecanoate; (c) an intermediate serum testosterone level after receiving a single dose of testosterone undecanoate at steady state an intermediate dose of testosterone undecanoate; or (d) a combination thereof. In one aspect, the dose titration assessment comprises determining the serum testosterone level during a window period within two to eight hours after receiving a dose of testosterone undecanoate. Low serum testosterone can be defined as less than 500, 450, 400, 350, 300, 250 or 200 ng/dL. High serum testosterone can be defined as greater than 500, 550, 600, 650, 700, 750, 800 or 850 ng/dL. Intermediate serum testosterone can be defined as a range of values defined by low and high serum testosterone levels in the previous two sentences.
Typically, the unit dosage forms contain an amount of TU as described herein and one or more pharmaceutically acceptable carriers e.g., additives. In one aspect, the unit dosage form is a tablet or capsule. In one aspect, the unit dosage form has a pharmaceutically acceptable carrier lipophilic additive, a hydrophilic additive, a solidifying agent or a combination thereof. In one aspect, the unit dosage form when tested using a USP type 2 apparatus in about 1000 mL 8% w/v Triton X100 solution in water at 37.0±0.5 at 100 rpm releases at least 60 wt % TU at 15 minutes and less than 100 wt % TU at 15 minutes. In one aspect, the unit dosage form has a pharmaceutically acceptable carrier lipophilic additive, a hydrophilic additive, a solidifying agent, or a combination thereof. In one aspect, the unit dosage form when tested using a USP type 2 apparatus in about 1000 mL 8% w/v Triton X100 solution in water at 37.0±0.5 at 100 rpm releases less than 90 wt % TU at 30 minutes and greater than 90 wt % TU at 120 minutes. In one aspect, the unit dosage form when tested using a USP type 2 apparatus in about 1000 mL 8% w/v Triton X100 solution in water at 37.0±0.5 at 100 rpm releases greater than 90 wt % TU at 30 minutes. The unit dosage forms usually contain a lipophilic additive although this is not absolutely required. The dosage forms can also contain a hydrophilic additive, a solidifying agent, or one or more other additives. The pharmaceutically acceptable carriers a selected such that the oral dosage form is pharmaceutically equivalent, bioequivalent, in respect to serum testosterone levels to a capsule with the fill containing from 50 mg to 350 mg TU (e.g., 75 or 112.5 mg TU) at about 15 wt % loading, 63 wt % Maisine 35-1, 16 wt % Cremophor RH 40, and 6 wt % PEG 8000). In respect to bioequivalent formulations, in one aspect, bioequivalent refers to steady state. In another aspect, bioequivalent refers to single dose. In yet another aspect, bioequivalent refers to food effect bioequivalent. Food effect bioequivalent refers to bioequivalence of the formulation under low fat versus standard fat meals, standard fat versus high fat meals, low fat versus high fat meals or a combination thereof.
In one embodiment, specific examples of oral dosage forms that are bioequivalent, pharmaceutically equivalent or both, to a capsule with the fill containing from 50 mg to 350 mg TU (e.g., 75 or 112.5 mg TU) at about 15 wt % loading, 63 wt % Maisine 35-1, 16 wt % Cremophor RH 40, and 6 wt % PEG 8000) include tablets, capsules, sachets, lozenges, granules, powders, sprinkle, suspension, liquids or combinations thereof. In another embodiment, the dosage form is coated. In one embodiment, the solid composition can be a matrix. In one embodiment, the solid oral dosage form is a tablet or a capsule. In another embodiment oral dosage form is a multiparticulate oral dosage form. In another embodiment, the composition can be multiparticulate. Regardless of the type, the oral dosage forms or compositions can be formulated to provide immediate, modified, delayed, sustained, extended, and/or controlled release of the testosterone undecanoate. The immediate, modified, delayed, extended, pulsatile, and/or controlled release can be achieved by any method known in the art so long as it does not interfere with the function of the solid oral dosage forms. Non-limiting examples of such methods includes coatings, polymers, and the like. In one embodiment, the oral dosage form can be uncoated. In one embodiment the solid composition of the invention is a solid dispersion, solid solution, molecular dispersion, co-precipitate, amorphate, solidified suspension, admixture, eutectic mixture, melt extrude, drug-carrier complex, thermosetting system, or combinations thereof. Thus, the oral dosage form has a drug label indicating or the method includes that the oral testosterone replacement therapy (oral formulation) is taken (1) “WITH A MEAL” or (2) “WITH MEAL, BUT NOT ON EMPTY STOMACH” or (3) “WITH FAT CONTAINING FOOD” not specifying fat content. In an alternative aspect, the drug label may indicate or the method includes that the formulation is taken “WITH MEAL, BUT NOT LOW FAT”. In an alternative aspect, the drug label may indicate or the method includes that the formulation is taken “WITH MEAL, BUT NOT HIGH FAT”. In an alternative aspect, the drug label may indicate or the method includes that the formulation is taken “WITH STANDARD OR NORMAL MEAL”.
In some embodiments, the oral dosage forms the present invention can be manufactured as tablet or capsule dosage forms either by dry granulation methods, or by wet granulation methods. For example, testosterone undecanoate can be combined with one or more pharmaceutically acceptable carrier and blended to get a homogenous mixture which can be compressed into a tablet or disposed into a capsule. In another embodiment, the homogenous mixture can be kneaded with a binder solution to get a wet granulate mass which can be dried and sized, for example by passing through ASTM mesh #30. The resulting granules can be optionally blended with pharmaceutical aids such as diluents, lubricants, disintegrants etc., and disposed into capsules or compressed into tablets. In another particular case, the tablets can be coated. In one embodiment the tablet is a matrix tablet. In another embodiment, the tablet can be multi-layered tablet dosage form which can achieve release characteristics that can accommodate dose splitting.
The oral dosage forms can also be formulated using melt-extrusion processes alone or in combination with other known processes. For example, in one embodiment, an amount of testosterone undecanoate can be homogeneously combined with a sufficient amount of one or more carrier substances prior to undergoing extrusion. The carrier suitable for the compositions of this invention, specifically melt extrusion process, can be lipophilic or hydrophilic carrier. Combinations of lipophilic and hydrophilic carriers may also be used.
The terms “melt” and “melting” should be interpreted broadly, and include not only the alteration from a solid state to a liquid state, but can also refer to a transition to a glassy state or a rubbery state in which it is possible for one component of the mixture to get embedded more or less homogeneously into the other. In particular cases, one component can melt and the other component(s) can dissolve in the melt, thus forming a solution which, upon cooling, may form a solid composition having advantageous properties. In another particular case, one component can melt and the other component(s) can suspend thus forming a suspension which upon cooling may form a solid suspension having advantageous properties.
The melt-extruded solid compositions used to make the oral dosage forms of the present disclosure can be granular, multiparticulates, pellets, beads, mini-tablets or tablets. The melt-extruded solids can be used alone as the solid oral dosage form or can be disposed into capsules or formed into tablets.
The carrier for a melt-extruded composition and/or dosage form can include, but is not limited to, carriers such as ethyl cellulose, cellulose acetate phthalates, glyceryl distearate, acrylic acid and methacrylic acid copolymers, methyl methacrylate copolymers, ethoxyethyl methacrylates, cyanoethyl methacrylate, aminoalkyl methacrylate copolymer, poly(acrylic acid), poly(methacrylic acid), methacrylic acid alkylamide copolymer, poly(methyl methacrylate), poly(methacrylic acid) (anhydride), methyl methacrylate, polymethacrylate, stearic acid, poly(methyl methacrylate) copolymer, polyacrylamide, aminoalkyl methacrylate copolymer, poly(methacrylic acid anhydride), and glycidyl methacrylate copolymers.
In one embodiment, the carrier for a melt-extruded oral dosage form can be one or more pharmaceutically acceptable polymers including, but not limited to polyvinyl alcohol, polyvinyl pyrrolidone, polyethylene glycols having molecular weight of about 1000 to about 20,000, gelatin, carbomer, poloxamer, hydroxypropyl methyl cellulose; hydroxypropyl ethyl cellulose hydroxypropyl cellulose, and carboxymethyl cellulose. It is noteworthy that some pharmaceutical carriers can be used in more than one manufacturing process, such as a wet milling or dry milling process as well as a melt extrusion process.
In certain embodiments, the at least one pharmaceutically acceptable carrier of any pharmaceutical composition provided herein comprises at least one hydrophilic carrier. In specific embodiments, the hydrophilic carrier is a hydrophilic triglyceride. In more specific embodiments, the hydrophilic triglyceride is a polyoxylated castor oil, or a polyoxylated hydrogenated castor oil. In some embodiments, any pharmaceutical composition provided herein has a lipophilic carrier (e.g., additive) or combination of lipophilic carriers. In certain embodiments, any pharmaceutical composition provided herein comprises a lipophilic carrier and less than 10 wt % or less than 5 wt % of a hydrophilic carrier.
In one embodiment, the lipophilic additive can include a lipophilic surfactant.
As used herein a surfactant is considered to be a lipophilic surfactant when it has an HLB value of 10 or less. Various lipophilic surfactants can be used including, but not limited to mono-, di-glycerides of fatty acids like glyceryl monolinoleate (e.g., Maisine® 35-1), mono- and di glycerides of caprylic, capric acid (e.g., Capmul® MCM), glyceryl monooleate, reaction mixtures of alcohols or polyalcohols with a variety of natural and/or hydrogenated oils such as PEG-5 hydrogenated castor oil, PEG-7 hydrogenated castor oil, PEG-9 hydrogenated castor oil, PEG-6 corn oil (e.g., Labrafil® M 2125 CS), PEG-6 almond oil (e.g., Labrafil®M 1966 CS), PEG-6 apricot kernel oil (e.g., Labrafil®M 1944 CS), PEG-6 olive oil (e.g., Labrafil®M 1980 CS), PEG-6 peanut oil (e.g., Labrafil®M 1969 CS), PEG-6 hydrogenated palm kernel oil (e.g., Labrafil®. M 2130 BS), PEG-6 palm kernel oil (e.g., Labrafil® M 2130 CS), PEG-6 triolein (e.g., Labrafil® M 2735 CS), PEG-8 corn oil (e.g., Labrafil® WL 2609 BS), PEG-20 corn glycerides (e.g., Crovol® M40), PEG-20 almond glycerides (e.g., Crovol® A40), lipophilic polyoxyethylene-polyoxypropylene block co-polymers (e.g., Pluronic® L92, L101, L121 etc.); propylene glycol fatty acid esters, such as propylene glycol monolaurate (e.g., Lauroglycol FCC), propylene glycol ricinoleate (e.g., Propymuls), propylene glycol monooleate (e.g., Myverol P-O6), propylene glycol dicaprylate/dicaprate (e.g., Captex® 200), and propylene glycol dioctanoate (e.g., Captex® 800), propylene glycol mono-caprylate (e.g., Capryol® 90); propylene glycol oleate (e.g., Lutrol OP2000); propylene glycol myristate; propylene glycol mono stearate; propylene glycol hydroxy stearate; propylene glycol ricinoleate ; propylene glycol isostearate; propylene glycol mono-oleate; propylene glycol dicaprylate/dicaprate; propylene glycol dioctanoate; propylene glycol caprylate-caprate; propylene glycol dilaurate; propylene glycol distearate; propylene glycol dicaprylate; propylene glycol dicaprate; mixtures of propylene glycol esters and glycerol esters such as mixtures composed of the oleic acid esters of propylene glycol and glycerol (e.g., Arlacel® 186); sterol and sterol derivatives such as cholesterol, sitosterol, phytosterol, phytosterol fatty acid esters, PEG-5 soya sterol, PEG-10 soya sterol, PEG-20 soya sterol, and the like; glyceryl palmitostearate, glyceryl stearate, glyceryl distearate, glyceryl monostearate, or a combination thereof; sorbitan fatty acid esters such as sorbitan monolaurate (e.g., Arlacel 20), sorbitan monopalmitate (e.g., Span-40), sorbitan monooleate (e.g., Span-80), sorbitan monostearate, and sorbitan tristearate, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monooleate, sorbitan trioleate, sorbitan sesquioleate, sorbitan tristearate, sorbitan monoisostearate, sorbitan sesquistearate, and the like; fatty acids such as capric acid, caprylic acid, oleic acid, linoleic acid, myristic acid, menthol, menthol derivatives, lecithin, phosphatidyl choline, bile salts, and the like, and mixtures thereof. It is important to note that some lipophilic surfactants may also function as the solubilizer component of the compositions and oral dosage forms.
In one embodiment, the lipophilic surfactant can be selected from the group consisting of glyceryl monolinoleate (e.g., Maisine® 35-1), mono- and di glycerides of caprylic, capric acid (e.g., Capmul® MCM), glyceryl monooleate, propylene glycol mono caprylate, propylene glycol oleate, propylene glycol monostearate, propylene glycol monolaurate, propylene glycol mono-oleate, propylene glycol dicaprylate/dicaprate, sorbitan monooleate, PEG-5 hydrogenated castor oil, PEG-7 hydrogenated castor oil, PEG-9 hydrogenated castor oil, PEG-6 corn oil, PEG-6 almond oil, PEG-6 apricot kernel oil, PEG-6 olive oil, PEG-6 peanut oil, PEG-6 hydrogenated palm kernel oil, sorbitan monolaurate (e.g., Arlacel 20), sorbitan monopalmitate, sorbitan monooleate, sorbitan monostearate, sorbitan tristearate, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monooleate, sorbitan trioleate, sorbitan sesquioleate, sorbitan tristearate, sorbitan monoisostearate, and combinations thereof. In some embodiments, the lipophilic surfactants can comprise at least about 10, 20, 30, 40, 50, 60, 70, 80, or 90 wt % of the total pharmaceutically acceptable carrier. It should be noted that the combinations of two or more lipophilic surfactants from the same or different classes therein are also within the scope of this invention and are together can be referred to as the lipophilic surfactant, unless otherwise stated.
In one embodiment, the composition/dosage form has a hydrophilic additive or a hydrophilic additive which can be a hydrophilic surfactant. A surfactant is considered to be a hydrophilic surfactant when it has an HLB value of greater than 10. Non-limiting examples of hydrophilic surfactants include non-ionic surfactants, ionic surfactants and zwitterionic surfactants. Specifically the hydrophilic surfactants suitable for the current invention include, but not limited to alcohol-oil transesterification products; polyoxyethylene hydrogenated vegetable oils; polyoxyethylene vegetable oils; alkyl sulphate salts, dioctyl sulfosuccinate salts; polyethylene glycol fatty acids esters; polyethylene glycol fatty acids mono- and di-ester mixtures; polysorbates, polyethylene glycol derivatives of tocopherol and the like It should be noted that the combinations of two or more hydrophilic surfactants from the same or different classes are within the scope of this invention and are together can be referred to as the hydrophilic surfactant unless explicitly specified. In one embodiment, the hydrophilic additive can be a hydrophilic surfactant. Non-limiting examples of hydrophilic surfactants can include PEG-8 caprylic/capric glycerides, lauroyl macrogol-32 glyceride, stearoyl macrogol glyceride, PEG-40 hydrogenated castor oil, PEG-35 castor oil, sodium lauryl sulfate, sodium dioctyl sulfosuccinate, polyethylene glycol fatty acids mono- and di-ester mixtures, polysorbate 80, polysorbate 20, polyethylene glycol 1000 tocopherol succinate, phytosterols, phytosterol fatty acid esters, and mixtures thereof.
Suitable additives utilized in various embodiments described herein include, by way of non-limiting example, adsorbing agents, anti-adherents, anticoagulants, antifoaming agents, antioxidants, anti-caking agents, anti-static agents, binders, bile acids, bufferants, bulking agents, chelating agents, coagulants, colorants, co-solvent, opaquants, congealing agents, coolants, cryoprotectants, diluents, dehumidifying agents, desiccants, desensitizers, disintegrants, dispersing agents, enzyme inhibitors, glidants, fillers, hydrating agent, super disintegrants, gums, mucilages, hydrogen bonding agents, enzymes, flavorants, humectants, humidifying agents, lubricant oils, ion-exchange resins, lubricants, plasticizers, pH modifying agents, preservatives, solidifying agent, solvents, solubilizers, spreading agent sweeteners, stabilizers, surface area enhancing agents, suspending agent, thickeners, viscosity increasing agents, waxes and mixtures thereof.
Some non-limiting examples of the additives suitable for the present disclosure may be: alcohols and/or polyols (e.g., ethanol, isopropanol, butanol, benzyl alcohol, ethylene glycol, propylene glycol, glycerol, sorbitol, mannitol, dimethyl isosorbide, polyethylene glycol, fatty acid alcohol, vinyl alcohol polypropylene glycol, polyvinylalcohol, tocopherols, cellulose cyclodextrins, other derivatives, forms, mixtures thereof, or the like); ethers of polyethylene glycols having an average molecular weight of about 200 to about 20,000 (e.g., tetrahydrofurfuryl alcohol PEG ether, methoxy PEG, or the like); amides (e.g., 2-pyrrolidone, 2-piperidone, 8-caprolactam, N-alkylpyrrolidone, N-hydroxyalkylpyrrolidone, N-alkylpiperidone, N-alkylcaprolactam, dimethylacetamide, polyvinylpyrrolidone and the like.); esters (e.g. ethyl propionate, tributylcitrate, acetyl triethylcitrate, acetyl tributyl citrate, triethylcitrate, ethyl oleate, ethyl caprylate, ethyl butyrate, triacetin, propylene glycol monoacetate, propylene glycol diacetate, 8-caprolactone and isomers thereof, 6-valerolactone and isomers thereof, gamma-butyrolactone and isomers thereof; and other additives known in the art, such as dimethyl acetamide, dimethyl isosorbide, N-methylpyrrolidones, monooctanoin, diethylene glycol monoethyl ether, or the like); amino acids (e.g., p-aminobenzamidine, sodium glycocholate) mesylate; amino acids and modified amino acids (e.g., aminoboronic acid derivatives and n-acetylcysteine; peptides and modified peptides (e.g., bacitracin, phosphinic acid dipeptide derivatives, pepstatin, antipain, leupeptin, chymostatin, elastin, bestatin, phoshporamindon, puromycin, cytochalasin potatocarboxy peptidase inhibitor, amastatin, or the like); polypeptide protease inhibitors; mucoadhesive polymers (e.g., polyacrylate derivatives, chitosan, cellulosics, chitosan-EDTA, chitosan-EDTA-antipain, polyacrylic acid, carboxymethyl cellulose etc.) or the like; or combinations thereof.
Some more examples of suitable additives for compositions and/or dosage forms described herein include, by way of non-limiting example, talc, magnesium stearate, silica (e.g., fumed silica, micronized silica, magnesium aluminum silicate etc.) and/or derivatives, polyethylene glycols, surfactants, waxes, oils, cetyl alcohol, polyvinyl alcohol, stearic acid, stearic acid salts, stearic acid derivatives, starch, hydrogenated vegetable oils, hydrogenated castor oils, sodium benzoate, sodium acetate, leucine, PEG, alkyl sulfate salts; acetylated monoglycerides; long-chain alcohols; silicone derivatives; butylated hydroxy toluene (BHT), butylated hydroxyl anisole (BHA), gallic acid, propyl gallate, ascorbic acid, ascorbyl palmitate, 4-hydroxymethyl-2,6-di-tert-butyl phenol, dry starch, dry sugars, polyvinyl pyrrolidones, starch paste, methacrylic copolymers, bentonite, sucrose, polymeric cellulose derivatives, shellac, sugar syrup; corn syrup; polysaccharides, acacia, tragacanth, guar gum, xanthan gums; alginates; gelatin; gelatin hydrolysate; agar; sucrose; dextrose; PEG, vinyl pyrrolidone copolymers, poloxamers; pregelatinized starch, sorbitol, glucose); acetic acid, hydrochloric acid, hydrobromic acid, hydriodic acid, sulfuric acid, nitric acid, boric acid, phosphoric acid, acetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acid, amino acids, ascorbic acid, benzoic acid, boric acid, butyric acid, carbonic acid, citric acid, fatty acids, formic acid, fumaric acid, gluconic acid, hydroquinosulfonic acid, isoascorbic acid, lactic acid, maleic acid, methanesulfonic acid, oxalic acid, para-bromophenylsulfonic acid, propionic acid, p-toluenesulfonic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, thioglycolic acid, toluenesulfonic acid and uric acid, vinegar, pharmaceutically acceptable bases, such as an amino acid, an amino acid ester, ammonium hydroxide, potassium hydroxide, sodium hydroxide, sodium hydrogen carbonate, aluminum hydroxide, calcium carbonate, magnesium hydroxide, magnesium aluminum silicate, synthetic aluminum silicate, synthetic hydrotalcite, magnesium aluminum hydroxide, diisopropylethylamine, ethanolamine, ethylenediamine, triethanolamine, triethylamine, triisopropanolamin; salt of a pharmaceutically acceptable cation and an anion; EDTA and EDTA salts; titanium dioxide, food dyes, lakes, natural vegetable colorants, iron oxides, silicates, sulfates, magnesium hydroxide and aluminum hydroxide; halogenated hydrocarbons, trichloroethane, trichloroethylene, dichloromethane, fluorotrichloromethane, diethylether, trehalose, phosphates, citric acid, tartaric acid, gelatin, dextran and mannitol, lactose, mannitol, sodium chloride, potassium chloride, spray-dried lactose, hydrolyzed starches, directly compressible starch, microcrystalline cellulose, cellulosic derivatives, sorbitol, sucrose, sucrose-based materials, calcium sulfate, dibasic calcium phosphate, dextrose, croscarmellose sodium, starch, starch derivatives, clays, gums, cellulose, cellulose derivatives, alginates, crosslinked polyvinylpyrrolidone, sodium starch glycolate and microcrystalline cellulose, magnesium oxide, magnesium carbonates; desensitizers, spray-dried flavors, essential oils, ethyl vanillin, styrene/divinyl benzene copolymers, quaternary ammonium compounds, polyethylene glycol, citrate esters (such as triethyl citrate, acetyl triethyl citrate, acetyltributyl citrate), acetylated monoglycerides, glycerin, triacetin, propylene glycol, phthalate esters (e.g., diethyl phthalate, dibutyl phthalate), castor oil, sorbitol and dibutyl sebacate, ascorbic acid, boric acid, sorbic acid, benzoic acid, and salts thereof, parabens, phenols, benzyl alcohol, and quaternary ammonium compounds; alcohols, ketones, esters, chlorinated hydrocarbons water; sweeteners (e.g., maltose, sucrose, glucose, sorbitol, glycerin and dextrins, aspartame, saccharine, saccharine salts, glycyrrhizin), viscosity modifiers, sugars, polyvinylpyrrolidone, cellulosics, polymers, gums and/or alginates.
In one embodiment, additives may also be materials such as proteins (e.g., collagen, gelatin, Zein, gluten, mussel protein, lipoprotein); carbohydrates (e.g., alginates, carrageenan, cellulose derivatives, pectin, starch, chitosan); gums (e.g., xanthan gum, gum Arabic); spermaceti; natural or synthetic waxes; carnuaba wax; fatty acids (e.g., stearic acid, hydroxystearic acid); fatty alcohols; sugars; shellacs, such as those based on sugars (e.g., lactose, sucrose, dextrose) or starches; polysaccharide-based shellacs (e.g., maltodextrin and maltodextrin derivatives, dextrates, cyclodextrin and cyclodextrin derivatives); cellulosic-based polymers (e.g., ethyl cellulose, methyl cellulose, microcrystalline cellulose, sodium carboxymethyl cellulose, hydroxypropylmethyl cellulose, ethyl cellulose, hydroxypropyl cellulose, HPMC acid succinates, cellulose acetate, cellulose nitrate, cellulose acetate butyrate, cellulose acetate trimellitate, carboxymethylethyl cellulose, hydroxypropylmethyl cellulose phthalate), shellacs; inorganics, such as dicalcium phosphate, hydroxyapatite, tricalcium phosphate, talc and titania; polyols, such as mannitol, xylitol and sorbitol; polyethylene glycol esters; and polymers, such as alginates, poly(lactide coglycolide), gelatin, crosslinked gelatin, and agar-agar. Non-limiting examples of compounds (e.g., additives) that can be used as at least a part of the pharmaceutically acceptable carrier include without limitation celluloses; dextrins, gums, carbomers, methacrylates, sugars, lactoses, inorganic carbonates, oxides, chlorides, sulphates and the like; salts of calcium; salts of magnesium; salts of fatty acids; inorganic and organic acids, bases and salts; propylene glycol; glycerols; fatty acids; fatty alcohols; fatty acid esters; glycerol esters; mono-, di- or triglycerides; edible oils; omega oils; vegetable oils, hydrogenated vegetable oils; partially or fully hydrogenated vegetable oils; glycerol esters of fatty acids; waxes; alcohols; gelatin; polyethylene glycol; polyethylene oxide co-polymers; silicates; antioxidants, tocopherols, sugar stearates, starches, shellac, resins, proteins, acrylates; methyl copolymers; polyvinyl alcohol; starch; phthalates; and combinations thereof.
In one embodiment, the additive may include at least one component selected from celluloses, dextrins, gums, carbomers, methacrylates, inorganic carbonates, salts of calcium, salts of magnesium, fatty acids, fatty acid esters, gelatin, lactoses, polyethylene glycol, polyethylene oxide co-polymers, silicates, partially hydrogenated vegetable oils, fully hydrogenated vegetable oils, waxes, antioxidants, tocopherol, sugar stearates, starches, shellac, resins, proteins, and combinations thereof.
In another embodiment, the additive may include at least one component selected from celluloses, dextrins, gums, carbomers, methacrylates, sugars, lactoses, inorganic carbonates, salts of calcium, salts of magnesium, salts of fatty acids, inorganic and organic acids, bases and salts, propylene glycol, glycerols, fatty acids, fatty alcohols, fatty acid esters, glycerol esters, mono-glycerol esters of fatty acids, di-glycerol esters of fatty acids, mixtures of mono-glycerol and di-gylcerol esters of fatty acids, omega oils, waxes, alcohols, gelatin, polyethylene glycol, polyethylene oxide co-polymers, silicates, antioxidants, tocopherol, sugar stearates, starches, shellac, resins, proteins, acrylates, methyl copolymers, polyvinyl alcohol, starch, phthalates, and combinations thereof.
Non-limiting examples of additives as release modulators that may be used include lipophilic resins; ethyl cellulose (EC), methylethyl cellulose (MEC), carboxymethyl ethylcellulose (CMEC), hydroxyethyl cellulose (HEC), cellulose acetate (CA), cellulose propionate (CPr), cellulose butyrate (CB), cellulose acetate butyrate (CAB), cellulose acetate phthalate (CAP), cellulose acetate trimellitate (CAT), hydroxypropyl methyl cellulose phthalate (HPMCP), hydroxypropyl methyl cellulose acetate succinate (HPMCAS), hydroxypropyl methyl cellulose acetate trimellitate (HPMCAT), ion-exchange resin; poloxamers; and ethylhydroxy ethylcellulose (EHEC) tocopherol; shellac; and combinations thereof. Non-limiting examples of lipidic lipophilic release modulators include fatty acids; mono-, di-, tri-esters of fatty acids with glycerol; sucrose esters with fatty acids; cetyl alcohol; stearic acid; glyceryl monostearate; glyceryl distearate; glyceryl tristearate; glyceryl palmitostearate; hydrogenated castor oil; butyl and glycol esters of fatty acids; oleic acid; cetyl alcohol; stearyl alcohol; cetostearyl alcohol; hydrogenated vegetable oil; waxes; bees wax; lard; omega fatty acid esters; hydrogenated soybean oil; hydrogenated vegetable oil; hydrogenated cottonseed and castor oil; partially hydrogenated soybean oil; partially hydrogenated castor oil; partially soy and cottonseed oil; phospholipids; hydrogenated oils, and their derivatives and combinations thereof.
In some embodiments, the pharmaceutical composition (e.g., oral dosage form) provided herein is formulated, e.g., with a viscosity enhancing agent or solidifying agent, to provide a solid, a semi-solid, a gel, a jelly, a paste, or the like. In some embodiments, the oral dosage form is a liquid. Non-limiting examples of formulations (and for use in the methods described herein) are given in the tables below.
Bioequivalent, pharmaceutically equivalent formulations having the drug label as described herein or for use in the method included herein can include those described about in Tables A-E or e.g., in reference to a formulation having 50 mg to 350 mg testosterone undecanoate (e.g., in one aspect either 75 mg or 112.5 mg TU) at about 15 wt % loading, about 63 wt % Maisine 35-1, about 16 wt % Cremophor RH 40, and about 6 wt % PEG 8000 as follows.
The following examples are provided to promote a more clear understanding of certain embodiments of the present invention, and are in no way meant as a limitation thereon.
This study was a single-center, open-label, randomized, cross-over, single-dose, four period, four-treatment study to examine the effect of food (fasted vs. high fat) and fat content of food on pharmacokinetics of testosterone & metabolites. 14 subjects were enrolled and 13 completed the study. 225 mg of TU (2 capsules (capsule fill containing 112.5 mg TU at about 15 wt % loading, 63 wt % Maisine 35-1, 16 wt % Cremophor RH 40, and 6 wt % PEG 8000) administered with:
The meals were as follows in Table I with quantity specified as grams (g) or [% total calories].
The results from the clinical trial are summarized in Table II below, which demonstrates bioequivalence for Cmax and Cavg for a standard meal versus a low fat meal or high fat meal and low fat versus high fat meals.
Thus, it was surprisingly discovered that oral testosterone undecanoate compositions can be administered to hypogonadal males with a meal without fat content of the meal substantially effecting bioavailability. This result is unexpected and in direct contrast to the results obtained with other testosterone undecanoate oral formulations reported in the literature whose bioavailability is dependent on meal fat content.
Given this information one of ordinary skillin the present arts would be capable of providing oral testosterone undecanoate formulation that are bioequivalent to the formulation used in this study, that are bioequivalent for Cmax, AUC(0-t), AUC(0-∞), Cavg, or a combination thereof at low, standard, and high fat conditions as well as standard versus low fat, standard versus high fat and low versus high fat.
The results of this study are also summarized in Tables III & IV below.
130% total calories derived from fat content in the meal consistent with Phase 3 recommended meal
215% total calories derived from fat content in the meal
350% total calories derived from fat content in the meal
150% total calories derived from fat content in the meal
Thus, these results support a drug label indicating that the oral testosterone replacement therapy is taken (1) “WITH A MEAL” or (2) “WITH MEAL, BUT NOT ON EMPTY STOMACH” or (3) “WITH FAT CONTAINING FOOD” not specifying fat content. In the alternative, the drug label may indicate “TAKE IT WITH MEAL, BUT NOT LOW FAT”. In another alternative, the drug label may indicate “TAKE IT WITH MEAL, BUT NOT HIGH FAT”. It yet another alternative, the drug label may indicate “TAKE IT WITH STANDARD OR NORMAL MEAL”.
The ordinary skilled artisan in view of these results can design and test formulations for bioequivalence (e.g., food effect bioequivalence) using the present disclosure.
Formulations for testing in a food effect study as described in Example 1 (or another appropriate designed study) can be designed e.g., by:
Typically, these formulations will be suited for soft gelatin or hard gelatin capsules. Other dosage forms are also contemplated for use in the present disclosure including tablets, sachets, lozenges, granules, powders, sprinkle, suspension, liquids or combinations thereof.
To determine if a Test formulation is bioequivalent to the formulation used in Example 1, a bioequivalence study is performed under the same or similar conditions. One of ordinary skill in the art can design and perform a bioequivalence study in view of the results presented in Example 1. Test formulations can be generated according to this disclosure or more particularly Example 2. The bioequivalence study is one that may support the filing of an Abbreviated New Drug Application at the US FDA or similar application in jurisdictions outside of the United States with the appropriate regulatory agency.
It is understood that the above-described various types of compositions, dosage forms and/or modes of applications are only illustrative of preferred embodiments of the present invention. Numerous modifications and alternative arrangements may be devised by those skilled in the art without departing from the spirit and scope of the present invention and the appended claims are intended to cover such modifications and arrangements. Thus, while the present invention has been described above with particularity and detail in connection with what is presently deemed to be the most practical and preferred embodiments of the invention, it will be apparent to those of ordinary skill in the art that variations including, but not limited to, variations in size, materials, shape, form, function and manner of operation, assembly and use may be made without departing from the principles and concepts set forth herein.
This application is a continuation of U.S. patent application Ser. No. 15/861,492, filed Jan. 3, 2018, which is a continuation of U.S. patent application Ser. No. 15/183,691, filed Jun. 15, 2016, which claims the benefit of U.S. Provisional Application No. 62/175,931 filed Jun. 15, 2015 and U.S. Provisional Application No. 62/253,292 filed Nov. 10, 2015, each of which is incorporated by reference in their entireties.
| Number | Name | Date | Kind |
|---|---|---|---|
| 2680749 | Cawley et al. | Jun 1954 | A |
| 2742487 | Robledano | Apr 1956 | A |
| 3097139 | Thorp | Jul 1963 | A |
| 3097144 | Banker | Jul 1963 | A |
| 3164520 | Huber | Jan 1965 | A |
| 3266991 | Wettstein et al. | Aug 1966 | A |
| 3510561 | Koh | May 1970 | A |
| 4098802 | Van der Vies | Jul 1978 | A |
| 4147783 | Van der Vies | Apr 1979 | A |
| 4156719 | Sezaki et al. | May 1979 | A |
| 4177188 | Hansen et al. | Dec 1979 | A |
| 4196188 | Besins | Apr 1980 | A |
| 4220599 | Van der Vies | Sep 1980 | A |
| 4239754 | Sache et al. | Dec 1980 | A |
| 4388307 | Cavanak | Jun 1983 | A |
| 4439432 | Peat | Mar 1984 | A |
| 4572915 | Crooks | Feb 1986 | A |
| 4579730 | Kidron et al. | Apr 1986 | A |
| 4628052 | Peat | Dec 1986 | A |
| 4628098 | Nohara et al. | Dec 1986 | A |
| 4654327 | Teng | Mar 1987 | A |
| 4656161 | Herr | Apr 1987 | A |
| 4689333 | Nohara et al. | Aug 1987 | A |
| 4695450 | Bauer | Sep 1987 | A |
| 4703042 | Bodor | Oct 1987 | A |
| 4713246 | Begum et al. | Dec 1987 | A |
| 4717569 | Harrison et al. | Jan 1988 | A |
| 4717596 | Barbee et al. | Jan 1988 | A |
| 4719239 | Muller et al. | Jan 1988 | A |
| 4727109 | Schmidt et al. | Feb 1988 | A |
| 4731384 | Dell | Mar 1988 | A |
| 4795327 | Gaylord et al. | Jan 1989 | A |
| 4832952 | Hersh et al. | May 1989 | A |
| 4834965 | Martani et al. | May 1989 | A |
| 4849227 | Cho | Jul 1989 | A |
| 4867984 | Patel | Sep 1989 | A |
| 4874795 | Yesair | Oct 1989 | A |
| 4880634 | Speiser | Nov 1989 | A |
| 4895726 | Curtet et al. | Jan 1990 | A |
| 4897269 | Mezei | Jan 1990 | A |
| 4900734 | Maxson et al. | Feb 1990 | A |
| 4925672 | Gremm | May 1990 | A |
| 4944949 | Story | Jul 1990 | A |
| 4961890 | Bover | Oct 1990 | A |
| 4963540 | Maxson et al. | Oct 1990 | A |
| 4994439 | Longenecker et al. | Feb 1991 | A |
| 5023108 | Bageria et al. | Jun 1991 | A |
| 5026560 | Makino et al. | Jun 1991 | A |
| 5035891 | Runkel et al. | Jul 1991 | A |
| 5045321 | Makino et al. | Sep 1991 | A |
| 5057319 | Gottwald | Oct 1991 | A |
| 5071643 | Yu et al. | Dec 1991 | A |
| 5091187 | Haynes | Feb 1992 | A |
| 5091188 | Haynes | Feb 1992 | A |
| 5093132 | Makino et al. | Mar 1992 | A |
| 5104656 | Seth et al. | Apr 1992 | A |
| 5120710 | Liedtke | Jun 1992 | A |
| 5140021 | Maxon et al. | Aug 1992 | A |
| 5145684 | Liversidge | Sep 1992 | A |
| 5152997 | Ebert et al. | Oct 1992 | A |
| 5206219 | Desai | Apr 1993 | A |
| 5244925 | Wretlind | Sep 1993 | A |
| 5252339 | Cristofori et al. | Oct 1993 | A |
| 5270005 | Raible | Dec 1993 | A |
| 5270055 | Moest | Dec 1993 | A |
| 5300529 | Narayanan | Apr 1994 | A |
| 5340589 | Stetsko et al. | Aug 1994 | A |
| 5342625 | Hauer et al. | Aug 1994 | A |
| 5350741 | Takada | Sep 1994 | A |
| 5364632 | Benita et al. | Nov 1994 | A |
| 5374446 | Ferenz et al. | Dec 1994 | A |
| 5376688 | Morton et al. | Dec 1994 | A |
| 5380535 | Geyer et al. | Jan 1995 | A |
| 5384133 | Boyes et al. | Jan 1995 | A |
| 5389382 | List et al. | Feb 1995 | A |
| 5403593 | Royce | Apr 1995 | A |
| 5433959 | Makino et al. | Jul 1995 | A |
| 5444041 | Owen | Aug 1995 | A |
| 5500224 | Vranckx et al. | Mar 1996 | A |
| 5532002 | Story | Jul 1996 | A |
| 5539000 | Leonard | Jul 1996 | A |
| 5543393 | Kim et al. | Aug 1996 | A |
| 5545628 | DeBoeck et al. | Aug 1996 | A |
| 5560931 | Eickhoff et al. | Oct 1996 | A |
| 5571533 | Santus et al. | Nov 1996 | A |
| 5571536 | Eickhoff et al. | Nov 1996 | A |
| 5573783 | Desieno et al. | Nov 1996 | A |
| 5589455 | Woo | Dec 1996 | A |
| 5589513 | Magyar et al. | Dec 1996 | A |
| 5593971 | Tschollar et al. | Jan 1997 | A |
| 5614491 | Walch et al. | Mar 1997 | A |
| 5616330 | Kaufman et al. | Apr 1997 | A |
| 5622721 | Dansereau et al. | Apr 1997 | A |
| 5624687 | Yano et al. | Apr 1997 | A |
| 5626869 | Nyqvist et al. | May 1997 | A |
| 5629021 | Wright | May 1997 | A |
| 5633015 | Gillis et al. | May 1997 | A |
| 5633226 | Owen | May 1997 | A |
| 5635520 | Uda | Jun 1997 | A |
| 5639474 | Woo | Jun 1997 | A |
| 5639478 | Makino et al. | Jun 1997 | A |
| 5639724 | Cavanak | Jun 1997 | A |
| 5645856 | Lacy et al. | Jul 1997 | A |
| 5646109 | Owen et al. | Jul 1997 | A |
| 5653987 | Modi et al. | Aug 1997 | A |
| 5656277 | Berlati et al. | Aug 1997 | A |
| 5656289 | Cho et al. | Aug 1997 | A |
| 5665379 | Herslof et al. | Sep 1997 | A |
| 5681584 | Savatano et al. | Oct 1997 | A |
| 5686105 | Kelm et al. | Nov 1997 | A |
| 5688761 | Owen et al. | Nov 1997 | A |
| 5698155 | Grosswald et al. | Dec 1997 | A |
| 5707648 | Yiv | Jan 1998 | A |
| 5714477 | Einarsson | Feb 1998 | A |
| 5726181 | Hausheer et al. | Mar 1998 | A |
| 5731355 | Jones et al. | Mar 1998 | A |
| 5736161 | Garces et al. | Apr 1998 | A |
| 5741512 | Hauer et al. | Apr 1998 | A |
| 5741822 | Yesair | Apr 1998 | A |
| 5747066 | Pittrof et al. | May 1998 | A |
| 5756450 | Hahn et al. | May 1998 | A |
| 5759997 | Cavanak | Jun 1998 | A |
| 5766629 | Cho et al. | Jun 1998 | A |
| 5767069 | Ko et al. | Jun 1998 | A |
| 5776495 | Duclos et al. | Jul 1998 | A |
| 5795883 | Hesch et al. | Aug 1998 | A |
| 5798333 | Sherman | Aug 1998 | A |
| 5811120 | Gibson et al. | Sep 1998 | A |
| 5817320 | Stone | Oct 1998 | A |
| 5827536 | Laruelle | Oct 1998 | A |
| 5846971 | Sangekar et al. | Dec 1998 | A |
| 5853748 | New | Dec 1998 | A |
| 5855905 | Oettel et al. | Jan 1999 | A |
| 5858398 | Cho | Jan 1999 | A |
| 5858401 | Bhalani et al. | Jan 1999 | A |
| 5866159 | Hauer et al. | Feb 1999 | A |
| 5874418 | Stella et al. | Feb 1999 | A |
| 5880148 | Edgar et al. | Mar 1999 | A |
| 5883109 | Gregg et al. | Mar 1999 | A |
| 5891469 | Amselem | Apr 1999 | A |
| 5891845 | Myers | Apr 1999 | A |
| 5916589 | Hauer et al. | Jun 1999 | A |
| 5922355 | Parikh et al. | Jul 1999 | A |
| 5948773 | Akiyama et al. | Sep 1999 | A |
| 5948825 | Takahashi et al. | Sep 1999 | A |
| 5962014 | Hauer et al. | Oct 1999 | A |
| 5962017 | Hauer et al. | Oct 1999 | A |
| 5965161 | Osblack | Oct 1999 | A |
| 5976574 | Gordon | Nov 1999 | A |
| 5981479 | Ko et al. | Nov 1999 | A |
| 5981586 | Pershadsingh | Nov 1999 | A |
| 5989583 | Amselem | Nov 1999 | A |
| 5993880 | Frost et al. | Nov 1999 | A |
| 6007840 | Hauer et al. | Dec 1999 | A |
| 6008192 | Al-Razzak et al. | Dec 1999 | A |
| 6013665 | DeMichele et al. | Jan 2000 | A |
| 6017560 | Makino et al. | Jan 2000 | A |
| 6022852 | Klokkers et al. | Feb 2000 | A |
| 6024978 | Hauer et al. | Feb 2000 | A |
| 6027747 | Terracol et al. | Feb 2000 | A |
| 6042847 | Kerc et al. | Mar 2000 | A |
| 6046177 | Stella et al. | Apr 2000 | A |
| 6057339 | Gregg | May 2000 | A |
| 6066653 | Gregg et al. | May 2000 | A |
| 6074670 | Stamm et al. | Jun 2000 | A |
| 6086376 | Moussa et al. | Jul 2000 | A |
| 6096338 | Lacy et al. | Aug 2000 | A |
| 6123962 | Makino et al. | Sep 2000 | A |
| 6160007 | DeMichele et al. | Dec 2000 | A |
| 6174547 | Dong et al. | Jan 2001 | B1 |
| 6180138 | Engh et al. | Jan 2001 | B1 |
| 6189486 | Lindholm | Feb 2001 | B1 |
| 6193985 | Sonne | Feb 2001 | B1 |
| 6221395 | Maggi et al. | Apr 2001 | B1 |
| 6224840 | Kim et al. | May 2001 | B1 |
| 6228399 | Parikh et al. | May 2001 | B1 |
| 6228400 | Lee | May 2001 | B1 |
| 6248363 | Patel et al. | Jun 2001 | B1 |
| 6255100 | Ko | Jul 2001 | B1 |
| 6267985 | Chen et al. | Jul 2001 | B1 |
| 6287594 | Wilson | Sep 2001 | B1 |
| 6294192 | Patel et al. | Sep 2001 | B1 |
| 6296876 | Odidi et al. | Oct 2001 | B1 |
| 6299904 | Shimizu et al. | Oct 2001 | B1 |
| 6303662 | Nagahama et al. | Oct 2001 | B1 |
| 6306825 | Cavanak | Oct 2001 | B1 |
| 6309663 | Patel et al. | Oct 2001 | B1 |
| 6328993 | Linder et al. | Dec 2001 | B1 |
| 6328994 | Shimizu et al. | Dec 2001 | B1 |
| 6340471 | Kershman et al. | Jan 2002 | B1 |
| 6342246 | Johnson et al. | Jan 2002 | B2 |
| 6361796 | Rudnic et al. | Mar 2002 | B1 |
| 6368634 | Remon | Apr 2002 | B1 |
| 6379705 | Mendes et al. | Apr 2002 | B1 |
| 6383471 | Chen et al. | May 2002 | B1 |
| 6383510 | Linder et al. | May 2002 | B1 |
| 6383517 | Qiu et al. | May 2002 | B1 |
| 6391342 | Henriksen et al. | May 2002 | B1 |
| 6432445 | Ambuhl et al. | Aug 2002 | B1 |
| 6444225 | Sherman | Sep 2002 | B1 |
| 6447806 | Gassmann et al. | Sep 2002 | B1 |
| 6451339 | Patel et al. | Sep 2002 | B2 |
| 6455518 | Zenke et al. | Sep 2002 | B2 |
| 6458373 | Lambert et al. | Oct 2002 | B1 |
| 6458383 | Chen et al. | Oct 2002 | B2 |
| 6465016 | Parikh et al. | Oct 2002 | B2 |
| 6468559 | Chen et al. | Oct 2002 | B1 |
| 6475519 | Minzer et al. | Nov 2002 | B1 |
| 6503894 | Dudley et al. | Jan 2003 | B1 |
| 6531139 | Gao et al. | Mar 2003 | B1 |
| 6569463 | Patel et al. | May 2003 | B2 |
| 6589552 | Stamm et al. | Jul 2003 | B2 |
| 6589562 | Shefer et al. | Jul 2003 | B1 |
| 6623755 | Chen et al. | Sep 2003 | B2 |
| 6630134 | Klein | Oct 2003 | B1 |
| 6652880 | Aylwin et al. | Nov 2003 | B1 |
| 6660286 | Lambert et al. | Dec 2003 | B1 |
| 6665880 | Pope | Dec 2003 | B2 |
| 6667048 | Lambert et al. | Dec 2003 | B1 |
| 6692766 | Rubinstein et al. | Feb 2004 | B1 |
| 6696482 | Schenoy et al. | Feb 2004 | B2 |
| 6720001 | Chen et al. | Apr 2004 | B2 |
| 6737082 | Picornell Darder | May 2004 | B1 |
| 6761903 | Chen et al. | Jul 2004 | B2 |
| 6881745 | Hayes et al. | Apr 2005 | B2 |
| 6887493 | Shefer et al. | May 2005 | B2 |
| 6913244 | Atkinson et al. | Jul 2005 | B1 |
| 6923988 | Patel et al. | Aug 2005 | B2 |
| 6977083 | Huebler et al. | Dec 2005 | B1 |
| 6982281 | Chen et al. | Jan 2006 | B1 |
| 7025979 | Neischlag et al. | Apr 2006 | B2 |
| 7138389 | Amory et al. | Nov 2006 | B2 |
| 7374779 | Chen et al. | May 2008 | B2 |
| 7658944 | Holm et al. | Feb 2010 | B2 |
| 7718640 | Hubler et al. | May 2010 | B2 |
| 8241664 | Dudley et al. | Aug 2012 | B2 |
| 8338395 | Hubler et al. | Dec 2012 | B2 |
| 8778922 | Giliyar et al. | Jul 2014 | B2 |
| 8865695 | Giliyar et al. | Oct 2014 | B2 |
| 9034858 | Giliyar et al. | May 2015 | B2 |
| 9205057 | Giliyar et al. | Dec 2015 | B2 |
| 9358241 | Giliyar et al. | Jun 2016 | B2 |
| 9498485 | Patel et al. | Jun 2016 | B2 |
| 9480690 | Giliyar et al. | Nov 2016 | B2 |
| 9757390 | Giliyar et al. | Sep 2017 | B2 |
| 9943527 | Giliyar et al. | Apr 2018 | B2 |
| 9949985 | Giliyar et al. | Apr 2018 | B2 |
| 10226473 | Giliyar et al. | Mar 2019 | B2 |
| 10561615 | Chickmath et al. | Feb 2020 | B2 |
| 10716794 | Giliyar et al. | Jul 2020 | B2 |
| 10799513 | Giliyar et al. | Oct 2020 | B2 |
| 10881671 | Giliyar et al. | Jan 2021 | B2 |
| 10973833 | Giliyar et al. | Apr 2021 | B2 |
| 11052096 | Giliyar et al. | Jul 2021 | B2 |
| 11311555 | Giliyar et al. | Apr 2022 | B2 |
| 11364249 | Giliyar et al. | Jun 2022 | B2 |
| 11364250 | Giliyar et al. | Jun 2022 | B2 |
| 11433083 | Giliyar et al. | Sep 2022 | B2 |
| 20010018069 | Johnson et al. | Aug 2001 | A1 |
| 20020006443 | Curatolo et al. | Jan 2002 | A1 |
| 20020013304 | Wilson et al. | Jan 2002 | A1 |
| 20020058066 | Tomohira et al. | May 2002 | A1 |
| 20020068693 | Jeng et al. | Jun 2002 | A1 |
| 20020085978 | Buenafe et al. | Jul 2002 | A1 |
| 20020102301 | Schwarz | Aug 2002 | A1 |
| 20020103139 | Weisspapir et al. | Aug 2002 | A1 |
| 20020183296 | Dudley et al. | Dec 2002 | A1 |
| 20030022875 | Wilson et al. | Jan 2003 | A1 |
| 20030072798 | Schwarz et al. | Apr 2003 | A1 |
| 20030077297 | Chen et al. | Apr 2003 | A1 |
| 20030082215 | Lemut et al. | May 2003 | A1 |
| 20030104048 | Patel et al. | Jun 2003 | A1 |
| 20030109508 | Yanni et al. | Jun 2003 | A1 |
| 20030209508 | Yanni et al. | Jun 2003 | A1 |
| 20030175326 | Thombre | Sep 2003 | A1 |
| 20030180352 | Patel et al. | Sep 2003 | A1 |
| 20030181431 | Hodgen | Sep 2003 | A1 |
| 20030186892 | Taneja | Oct 2003 | A1 |
| 20030216260 | Ruther | Nov 2003 | A1 |
| 20030216360 | Grawe et al. | Nov 2003 | A1 |
| 20030228358 | Perlman et al. | Dec 2003 | A1 |
| 20030235595 | Chen et al. | Dec 2003 | A1 |
| 20030236236 | Chen et al. | Dec 2003 | A1 |
| 20040002445 | Taneja | Jan 2004 | A1 |
| 20040002482 | Dudley et al. | Jan 2004 | A1 |
| 20040048896 | Phillips | Mar 2004 | A1 |
| 20040127476 | Kershaman et al. | Jul 2004 | A1 |
| 20050031693 | Babcock et al. | Feb 2005 | A1 |
| 20050032762 | Hubler et al. | Feb 2005 | A1 |
| 20050070516 | Wilson | Mar 2005 | A1 |
| 20050080075 | Nichols et al. | Apr 2005 | A1 |
| 20050096296 | Fikstad et al. | May 2005 | A1 |
| 20050096365 | Fikstad et al. | May 2005 | A1 |
| 20050100608 | Ebert | May 2005 | A1 |
| 20050101517 | De Nijs et al. | May 2005 | A1 |
| 20050171193 | Chen et al. | Aug 2005 | A1 |
| 20050176692 | Amory et al. | Aug 2005 | A1 |
| 20050209345 | Charman | Sep 2005 | A1 |
| 20050220825 | Funke et al. | Oct 2005 | A1 |
| 20050269251 | Cork | Dec 2005 | A1 |
| 20050287203 | De Nijs et al. | Dec 2005 | A1 |
| 20050287212 | Dong et al. | Dec 2005 | A1 |
| 20060003002 | Fikstad et al. | Jan 2006 | A1 |
| 20060034937 | Patel | Feb 2006 | A1 |
| 20060051406 | Parmar | Mar 2006 | A1 |
| 20060106004 | Brody et al. | May 2006 | A1 |
| 20060142257 | Nieschlag | Jun 2006 | A1 |
| 20070110777 | Joabsson et al. | May 2007 | A1 |
| 20070134336 | Worle et al. | Jun 2007 | A1 |
| 20070154533 | Dudley | Jul 2007 | A1 |
| 20070232548 | Taneja | Oct 2007 | A1 |
| 20080020053 | Persson et al. | Jan 2008 | A1 |
| 20080217692 | Anderson et al. | Sep 2008 | A1 |
| 20080317844 | Dudley et al. | Dec 2008 | A1 |
| 20080317850 | Hewitt et al. | Dec 2008 | A1 |
| 20080317859 | Sournac et al. | Dec 2008 | A1 |
| 20090074859 | Patel | Mar 2009 | A1 |
| 20100136105 | Chen et al. | Jun 2010 | A1 |
| 20100137271 | Chen et al. | Jun 2010 | A1 |
| 20100148675 | Meijer et al. | Jun 2010 | A1 |
| 20100173882 | Gilivar et al. | Jul 2010 | A1 |
| 20110039814 | Huatan et al. | Feb 2011 | A1 |
| 20110142945 | Chen et al. | Jun 2011 | A1 |
| 20110160168 | Dhingra | Jun 2011 | A1 |
| 20110251167 | Dudley | Oct 2011 | A1 |
| 20110263552 | Dhingra et al. | Oct 2011 | A1 |
| 20120135074 | Giliyar | May 2012 | A1 |
| 20120148675 | Chickmath et al. | Jun 2012 | A1 |
| 20120244215 | Giliyar et al. | Sep 2012 | A1 |
| 20120322780 | Giliyar et al. | Dec 2012 | A1 |
| 20130022674 | Dudley et al. | Jan 2013 | A1 |
| 20130023505 | Garfield et al. | Jan 2013 | A1 |
| 20130052263 | Fikstad et al. | Feb 2013 | A1 |
| 20130178454 | Bhasin et al. | Jul 2013 | A1 |
| 20130225544 | Nachaegari et al. | Aug 2013 | A1 |
| 20130226644 | Alonzo et al. | Aug 2013 | A1 |
| 20140178466 | Giliyar et al. | Jun 2014 | A1 |
| 20140179652 | Giliyar et al. | Jun 2014 | A1 |
| 20140303130 | Giliyar et al. | Oct 2014 | A1 |
| 20140309202 | Giliyar | Oct 2014 | A1 |
| 20150038475 | Chickmath et al. | Feb 2015 | A1 |
| 20150064243 | Chen et al. | Mar 2015 | A1 |
| 20150273067 | Patel | Oct 2015 | A1 |
| 20160193225 | Patel | Jul 2016 | A1 |
| 20160361322 | Patel | Dec 2016 | A1 |
| 20160367569 | Giliyar et al. | Dec 2016 | A1 |
| 20170056415 | Patel et al. | Mar 2017 | A1 |
| 20170246486 | Cazier et al. | Aug 2017 | A1 |
| 20180125857 | Giliyar et al. | May 2018 | A1 |
| 20180228816 | Giliyar et al. | Aug 2018 | A1 |
| 20180228817 | Gilivar et al. | Aug 2018 | A1 |
| 20180243320 | Giliyar et al. | Aug 2018 | A1 |
| 20180333422 | Chidambaram et al. | Nov 2018 | A1 |
| 20190240236 | Chidambaram et al. | Aug 2019 | A1 |
| 20190321374 | Patel et al. | Oct 2019 | A1 |
| 20190350942 | Patel et al. | Nov 2019 | A1 |
| 20190365780 | Giliyar et al. | Dec 2019 | A1 |
| 20200069701 | Giliyar et al. | Mar 2020 | A1 |
| 20200222425 | Patel et al. | Jul 2020 | A1 |
| 20200230152 | Giliyar et al. | Jul 2020 | A1 |
| 20200237781 | Giliyar et al. | Jul 2020 | A1 |
| 20200237782 | Giliyar et al. | Jul 2020 | A1 |
| 20200383997 | Giliyar et al. | Dec 2020 | A1 |
| 20210038615 | Giliyar et al. | Feb 2021 | A1 |
| 20210052604 | Giliyar et al. | Feb 2021 | A1 |
| 20210100816 | Giliyar et al. | Apr 2021 | A1 |
| 20210177865 | Giliyar et al. | Jun 2021 | A1 |
| Number | Date | Country |
|---|---|---|
| 2295028 | Jan 1999 | CA |
| 2302735 | Jan 2000 | CA |
| 1346274 | Apr 2002 | CN |
| 101217963 | Jul 2008 | CN |
| 2508615 | Sep 1975 | DE |
| 4412464 | Oct 1995 | DE |
| 10108614 | Sep 2002 | DE |
| 0036145 | May 1985 | EP |
| 0184942 | Jun 1986 | EP |
| 0537070 | Apr 1993 | EP |
| 0724877 | Aug 1996 | EP |
| 0981328 | Mar 2000 | EP |
| 0988858 | Mar 2000 | EP |
| 1103252 | May 2001 | EP |
| 0904064 | Oct 2001 | EP |
| 1624855 | Feb 2006 | EP |
| 1879456 | Jan 2008 | EP |
| 2000130 | Dec 2008 | EP |
| 2558073 | Sep 2014 | EP |
| 2647346 | Sep 1991 | FR |
| 2758459 | Jul 1998 | FR |
| 1264677 | Feb 1973 | GB |
| 1567515 | May 1980 | GB |
| 2098865 | Dec 1982 | GB |
| 2228198 | Aug 1990 | GB |
| S5266616 | Jun 1977 | JP |
| S52-148060 | Dec 1977 | JP |
| S5770824 | May 1982 | JP |
| H01139526 | Jun 1989 | JP |
| 5194209 | Aug 1993 | JP |
| 07041422 | Feb 1995 | JP |
| H07-508724 | Sep 1995 | JP |
| 09241152 | Sep 1997 | JP |
| 11049664 | Feb 1999 | JP |
| 11152227 | Jun 1999 | JP |
| 2001500368 | Jan 2001 | JP |
| 2001508445 | Jun 2001 | JP |
| 2001514626 | Sep 2001 | JP |
| 2002510311 | Apr 2002 | JP |
| 2002520377 | Jul 2002 | JP |
| 2003500368 | Jan 2003 | JP |
| 2005500347 | Jan 2005 | JP |
| 2008537960 | Oct 2008 | JP |
| 2008540451 | Nov 2008 | JP |
| 2246296 | Feb 2005 | RU |
| 2354381 | May 2009 | RU |
| 2482847 | May 2013 | RU |
| WO 8201649 | May 1982 | WO |
| WO 8402076 | Jun 1984 | WO |
| WO 8800059 | Jan 1988 | WO |
| WO 9218147 | Oct 1992 | WO |
| WO 9302664 | Feb 1993 | WO |
| WO 9306921 | Apr 1993 | WO |
| WO 9325192 | Dec 1993 | WO |
| WO 9408610 | Apr 1994 | WO |
| WO 9425068 | Nov 1994 | WO |
| WO 9501785 | Jan 1995 | WO |
| WO 9501786 | Jan 1995 | WO |
| WO 9524893 | Sep 1995 | WO |
| WO 9534287 | Dec 1995 | WO |
| WO 9617597 | Jun 1996 | WO |
| WO 9704749 | Feb 1997 | WO |
| WO 9740823 | Nov 1997 | WO |
| WO 9748382 | Dec 1997 | WO |
| WO 9800116 | Jan 1998 | WO |
| WO 9830205 | Jul 1998 | WO |
| WO 9833512 | Aug 1998 | WO |
| WO 9838984 | Sep 1998 | WO |
| WO 9850077 | Nov 1998 | WO |
| WO 9856357 | Dec 1998 | WO |
| WO 9900111 | Jan 1999 | WO |
| WO 9929300 | Jun 1999 | WO |
| WO 9940904 | Aug 1999 | WO |
| WO 9944584 | Sep 1999 | WO |
| WO 9948498 | Sep 1999 | WO |
| WO 0003753 | Jan 2000 | WO |
| WO 0059512 | Oct 2000 | WO |
| WO 03011300 | Feb 2003 | WO |
| WO 2004080383 | Sep 2004 | WO |
| WO 2006113505 | Oct 2006 | WO |
| WO 2007100614 | Sep 2007 | WO |
| WO 2010081032 | Jul 2010 | WO |
| WO 2010102737 | Sep 2010 | WO |
| WO 2011082384 | Jul 2011 | WO |
| WO 2011129812 | Oct 2011 | WO |
| WO 2012101016 | Aug 2012 | WO |
| Entry |
|---|
| Yin (Year: 2012). |
| Addo et al.; “Non Polar Extracts of Serum From Males Contain Covert Radioimmunoassayable Testosterone”; Steroids; (Sep. 1989); pp. 25-269; vol. 54(3). |
| Alvarez et al.; “The Role of Calcium Ions and Bile Salts on the Pancreatic Lipase-Catalyzed Hydrolysis of Triglyceride Emulsions Stabilized with Lecithin”; Pharmaceutical Research; (1989); pp. 449-457; vol. 6(6). |
| Andriol® Testocaps®; Consumer Medicine Information; (Sep. 2003). |
| Androderm® Product Label and Medication Guide; 1995; Labeler—Watson Pharma, Inc.; Revised Nov. 2013; 23 pages. |
| Androgel® Product Label and Medication Guide; May 2013; Labeler—AbbVie Inc.; Revised Oct. 2013; 28 pages. |
| Atkinson et al; “Long Term Experience with Testosterone Replacement Through Scrotal Skin; Testosterone: Action, Deficiency and Substitution”; Nieschlag, E. and Behre, HM, Eds.; (1998); pp. 365-388. |
| Aungst; “Intestinal Permeation Enhancers,” Journal of Pharmaceutical Sciences; (2000); pp. 429-442; vol. 89(4). |
| Baert et al.; “Analytical, biopharmaceutical and regulatory evaluation of topical testosterone preparations”; European Journal of Pharmaceutics and Biopharmaceutics; (2009); pp. 275-281; vol. 72; <doi: 10.1016/j.ejpb.2008.10.014 >. |
| Bagchus et al.; “Important Effect of Food on the Bioavailability of Oral Testosterone Undecanoate”; Pharmacotherapy: (2003); pp. 319-325; vol. 23(3). |
| Baluom et al.; “The Importance of Intestinal Residence Time of Absorption Enhancer on Drug Implication on Formulative Considerations”; International Journal of Pharmaceutics; (1998); pp. 21-30; vol. 176. |
| Bates et al.; “Bioavailability of Micronized Griseofulvin from Corn Oil-in-Water Emulsion, Aqueous Suspension, and Commercial Tablet Dosage Forms in Humans”; Journal of Pharmaceutical Sciences; (1975); pp. 793-797; vol. 64(5). |
| Beatch et al.; “Ventricular Fibrillation, an Uncontrolled Arrhythmia Seeking New Targets”; Drug Development Research Journal; (2002); pp. 45-52; vol. 55. |
| Bernkop-Schnurch; “The Use of Inhibitory Agents to Overcome the Enzymatic Barrier to Orally Administered Therapeutic Peptides and Proteins”; Journal of Controlled Release; (Apr. 1998); pp. 1-16; vol. 52(1-2). |
| Bhargava et al.; “Using Microemulsions for Drug Delivery”; Pharmaceutical Technology; (Mar. 1987); pp. 46-53. |
| Blystone et al.; “Toxicity and Carcinogenicity of Androstenedione in F344/N Rats and B6C3F2 Mice”; Food and Chemical Toxicology; (Sep. 2011); pp. 2116-2124; <doi: 10.1016/j.fct.2011.05.026.Epub2011May30 >. |
| Bugay; “Characterization of the Solid-State: Spectroscopic Techniques”; Advanced Drug Delivery Review; (May 16, 2001); pp. 43-65; vol. 48(1). |
| Burbello et al.; Sovremennye Lekarstvennyesredstava S-Pb Neva; (2004); p. 567. |
| Cantrill; “Which Testosterone Replacement Therapy”; Clinical Endocrinology Journal; (1984); pp. 97-107; vol. 21. |
| Charman et al.; “Physicochemical and Physiological Mechanisms for the Effects of Food on Drug Absorption: The Role of Lipids and pH”; Journal of Pharmaceutical Sciences; (1997); pp. 269-282; vol. 86(3). |
| Constantidides; “Lipid Microemulsion for Improving Drug Dissolution and Oral Absorption: Physical and Biopharmaceutical Aspect”; Pharmaceutical Research; (1995); pp. 1561-1572; vol. 12(11). |
| Depo-Testosterone® Product Label and Medication Guide; Sep. 2006; Labeler—Pharmacia & Upjohn Company; Revised Aug. 2013; 12 pages. |
| Emulsion; IUPAC Compendium of Chemical Terminology, 2nd Ed., 1997. |
| Frey et al.; “Bioavailability of Oral Testosterone in Males”; European Journal of Pharmacology; (1979); pp. 345-349; vol. 16. |
| Gennaro; “Surfactant Properties in Solution and Micelle Formation, Colloidal Dispersions”; Remington's Pharmaceutical Sciences; (1985); pp. 293-300; Chapter 20. |
| Goncharova et al.; “Preparation of Testosterone Esters”; Pharmaceutical Chemistry Journal; (Jul. 1973); pp. 427-428; vol. 7(7). |
| Gonzalo-Lumbrerars et al.; “HPLC Method Development for Testosterone Propionate and Cipionate in Oil-Based Injectables”; Journal of Pharmaceutical and Biomedical Analysis; (Jul. 15, 2005); pp. 757-762; vol. 38(4). |
| Gooren; “A Ten-year Safety Study of the Oral Androgen Testosterone Undecanoate”; Journal of Andrology: (1994); pp. 212-215; vol. 15(3). |
| Grahame-Smith et al; The Oxford Textbook of Clinical Pharmacology and Drug Therapy; (1992); pp. 25, 136-137; 2nd Edition; M. Meditsina Publishers; (English version included pp. 9-12, 122-124). |
| Healthline; “What are the symptoms of Hypogonadism?”; 1 page; [Internet]; [Retrieved on Apr. 1, 2014] [Retrieved from <URL: http://www.healthline.com/health/hypogonadism#Overview1 >]. |
| Hong, B.S., et al.; “Recent trends in the treatment of testosterone deficiency syndrome”; International Journal of Urology; (2007); pp. 981-985; vol. 14; The Japanese Urological Association; <doi: 10.1111/j.1442-2042.2007.01882.x >. |
| Hörter et al.; “Influence of Physiochemical Properties on Dissolution of Drugs in the Gastrointestinal Tract”; Advanced Drug Delivery Reviews; (1997); pp. 3-14; vol. 25. |
| Houwing et al.; “Pharmacokinetic Study in Women of Three Different Doses of a New Formulation of Oral Testosterone Undecanoate, Andriol Testocaps”, Pharmacotherapy; (2003); pp. 1257-1265; vol. 23(10). |
| Humberstone et al.; “Lipid-based Vehicles for the Oral Delivery of Poorly Water Soluble Drugs”; Advanced Drug Delivery Reviews; (1997) pp. 103-128. |
| Hutchison; “Digestible Emulsions and Microemulsions for Optimum Oral Delivery of Hydrophobic Drugs”; Bulletin Technique Gattefosse; (1994); pp. 67-74; vol. 87. |
| Javanbakht et al; “Pharmacokinetics of a Novel Testosterone Matrix Transdermal System In Health, Premenopausal Women and Women Infected with the Human Immunodeficiency Virus 1”; Journal of Clinical Endocrinology & Metabolism; (2000); pp. 2395-2401; vol. 85(7). |
| Johnson; “Gastrointestinal Physiology”; Department of Physiology; University of Texas Medical School: (1997); pp. 25-26, 93-106, 133-134, 136-137; Houston, Texas. |
| Julien; “A concise nontechnical guide to the actions, uses, and side effects of psychoactive drugs”; A Primer of Drug Action; (2001); pp. 5-6; 9th Edition. |
| Kalinchenko; “Testosterone—King Hormones, hormones kings”; The Journal; Sex and Life; (2004); pp. 12-22; [Retrieved on Mar. 26, 2010]; [Retrieved from <URL: http://www.laz.med.ru/interesting/publications/testosterone.html >]. |
| Köhn et al.; “A New Oral Testosterone Undecanoate Formulation”; World Journal of Urology; (Nov. 2003); pp. 311-315; vol. 21(5); <doi: 10.1007/s00345-003-0372-x>. |
| Langer; “New Methods of Drug Delivery”; Science; (Sep. 1990); pp. 1527-1533; vol. 249(4976). |
| Lecluyse et al.; “In Vitro Models for Selection of Development Candidates. Permeability Studies to Define Mechanisms of Absorption Enhancement”; Advanced Drug Delivery Reviews; (1997); pp. 163-183; vol. 23. |
| Leichtnam et al.; “Testosterone Hormone Replacement Therapy: State-of-the-Art and Emerging Technology”; Pharmaceutical Research; (2006); pp. 1117-1132; vol. 23(6). |
| LGC: Reference Standard Testosterone Undecanoate; Certificate of Analysis; (Jul. 5, 2015); 6 pages; LGC GmBH; Germany. |
| Lopez-Berestein et al. (Eds.); Liposomes in the Therapy of Infectious Disease and Cancer; (1989); pp. 353-365; Liss; New York. |
| MacGregor et al.; “Influence of Lipolysis on Drug Absorption From the Gastro-Intestinal Tract”; Advanced Drug Delivery Reviews; (1997); pp. 33-46; vol. 25. |
| Maisey et al; “Clinical Efficacy of Testosterone Undecanoate in Male Hypogonadism”; Clinical Endocrinology; (1981); pp. 625-629; vol. 14. |
| McAuley et al; “Oral Administration of Micronized Progesterone: A Review and More Experience”; Pharmacotherapy; (May 1996); pp. 453-457; vol. 16(3). |
| Meinert et al.; Clinical Trials: Design, Conduct and Analysis (Monographs in Epidemiology and Biostatistics; (1986); vol. 8. |
| Merck Index, “Alpha Tocopherol”; Monograph 09571; (2001-2004); Merck & Co. Inc. |
| Merck Index; “Amiodarone”; Monograph 504; (1996); p. 84; 12th Edition; Merck & Co., Inc. |
| Merck Index; “Carvedilo”; Monograph 01888; (2001-2004); Merck & Co., Inc. |
| Merck Index; “Fenofibrate”; Monograph 3978; (2006); pp. 679-680; 14th Edition; Merck & Co., Inc. |
| Merck Index; “Risperidone”; Monograph 08316; (2001-2004); Merck & Co., Inc. |
| Merck Index; “Shellac”; Monograph 8623; (1996); p. 8526; 12th Edition. |
| Merck Index; “Testosterone”; Monograph 9322; (1996); p. 9326; 12th Edition; Merck & Co., Inc. |
| Merck Index; “Vitamin E” and “Vitamin E Acetate”; Monographs 9931 and 9932; (1989); pp. 1579-1580; 11th Edition; Merck & Co., Inc. |
| Merck Index; “Vitamin E”; Monograph 10021; (2006); p. 1726; 14th Edition; Merck & Co., Inc. |
| Merck Index; “Ziprasidone”; Monograph 10224;(2001-2004); Merck & Co., Inc. |
| Merriam-Webster Dictionary; “Granule”; [Retrieved Dec. 17, 2009] [Retrieved from <URL: http://www.mw.com/dictionary/granule >]. |
| Mittal et al; “The Wide World of Micelles”; In: International symposium on Micellization, Solubilization, and Microemulsions, 7th Northeastern Regional Meeting of the American Society; Albany, New York; (1976); pp. 1-21; vol. 1 <ISBN: 0-306-31023-6(v.1) >. |
| Moellering; “Vancomycin: A 50-Year Reassessment”; Clinical Infectious Diseases; (2006); pp. S3-S4; vol. 42. |
| Muranishi; “Absorption Enhancers”; Critical Reviews in Therapeutic Drug Carrier Systems; (1990); pp. 1-33; vol. 7(1). |
| Muranishi; “Potential Absorption of Heparin from the Small Intestine and the Large Intestine in the Presence of Monoolein Mixed Micelles”; Chemical and Pharmaceutical Bulletin Journal; (1977); pp. 1159-1161; vol. 24(5). |
| Nieschlag et al.; “Plasma Androgen Levels in Men after Oral Administration of Testosterone or Testosterone Undecanoate”; Acta Endocrinologica; (1975); pp. 366-374; vol. 79(2); (Abstract). |
| Noguchi et al; “The Effect of Drug Lipophilicity and Lipid Vehicles on the Lymphatic Absorption of Various Testosterone Esters”; International Journal of Pharmaceutics; (May 1985); pp. 173-184; vol. 24(2-3). |
| Osol (Ed.); “Emulsions”; Remington's Pharmaceutical Sciences; (1975); pp. 327-339, 1452-1456; 15th Edition. |
| Pechersky et al.; “The Effects of Changes in Testosterone Level on the Development of Prostate Cancer;” Urology; (Sep. 2005); pp. 14-15; vol. 66, (Supplement 3A); 37. |
| Pechersky et al. “Androgen administration in middle-aged and aging men: effects of oral testosterone undecanoate on dihydrotestosterone, oestradiol and prostate volume”; International Journal of Andrology; (2002); pp. 119-125; vol. 25. |
| Pfeil et al.; “Current and Future Testosterone Delivery Systems for Treatment of the Hypogonadal Male;” Expert Opinion on Drug Delivery; (Apr. 21, 2008); pp. 471-481; vol. 5, No. 4; <doi: 10-1517/17425247.5.4.471 >. |
| Pouton; “Formulation of Self-Emulsifying Drug Delivery Systems”; Advanced Drug Delivery Reviews; (1997); pp. 47-58; vol. 25. |
| Pozo et al.; “Quantification of Testosterone Undecanoate in Human Hair by Liquid Chromatography-Tandem Mass Spectrometry”; Biomedical Chromatography; (Aug. 2009); pp. 873-880; vol. 23(8). |
| Remington; “Surfactant Properties in Solution and Micelle Formation”; The Science and Practice of Pharmacy; (1995); pp. 272-276; (19th Edition). |
| Reymond et al.; “In Vivo Model for Ciclosporin Intestinal Absorption in Lipid Vehicles”; Pharmaceutical Research; (1988); pp. 677-679; vol. 5(10). |
| S1 SEC Filing (Securities and Exchange Commission) for Clarus Therapeutics, Inc.; Filed May 23, 2014 with the Securities and Exchange Commission; 207 pages. |
| Saudek et al.; “A preliminary trial of the programmable implantable medication system for insulin delivery”; The New England Journal of Medicine; (Aug. 31, 1989); pp. 574-579; vol. 321. |
| Schnabel et al.; “The effect of food composition on serum testosterone levels after oral administration of Andriol Testocaps”; Clinical Endocrinology; (2007); pp. 579-585; vol. 66(4). |
| Schott; “Comments on Hydrophile-Lipophile Balance Systems”; Journal of Pharmaceutical Sciences; (Jan. 1990); pp. 87-88; vol. 79(1); American Pharmaceutical Association. |
| sciencelab.com; “MSDS: Glyceryl Monooleate”; Material Safety Data Sheet; (Oct. 2005); 5 pages; <URL: www.sciencelab.com >. |
| Sefton; “Implantable Pumps”; Critical Reviews in Biomedical Engineering; (1987); pp. 201-240; vol. 14, No. 3; (Abstract); [Sourcelink] <URL: http://www.ncbi.nlm.nih.gov/pubmed/3297487 >. |
| Seidman et al.; “Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression”; Journal of Affective Disorders; (1998); pp. 157-161; vol. 48. |
| Shackleford et al., “Contribution of Lymphatically Transported Testosterone Undecanoate to the Systemic Exposure of Testosterone after Oral Administration of two Andriol Formulations in Conscious Lymph Duct-Cannulated Dogs”; The Journal of Pharmacology and Experimental Therapeutics; (2003); pp. 925-933; vol. 306(3). |
| Shanghai PI Chemicals Ltd.; “MSDS: Testosterone Undecanoate”; Material Safety Data Sheet; (2007); [Retrieved on Jun. 3, 2009] [retrieved from <URL: http://www.pipharm.com/product/msds-13457.pdf >]. |
| Stedman's Medical Dictionary; “Dehydro-e-epiandrosterone”; “Dehydroisoandroteron”; and “Steriod”; (1972); pp. 329, 1195-1197; 22nd Edition; Williams & Wilkins Co. |
| Stedman's Medical Dictionary; “Hydroxy-Acid and Vitamin E”; (1973); pp. 595, 14000; 22nd Edition; Williams & Wilkins Co. |
| Stedman's Medical Dictionary; “Surfactants”; (1972); p. 1225; 22nd Edition; Williams & Wilkins Co. |
| Stedman's Medical Dictionary; “Surfactants”; (2006); 28nd) Edition; Williams & Wilkins Co. |
| Swerdloff, et al; “Long Term pharmaceokinetics of transdermal testosterone gel in hypogonadal men”. Journal of Clinical Endocrinology & Metabolism; (2000); pp. 4500-4510; vol. 85. |
| Tarr et al.; “Enhanced Intestinal Absorption of Cyclosporine in Rats Through the Reduction of Emulsion Droplet Size”; Pharmaceutical Research; (1989); pp. 40-43; vol. 6(1). |
| Tarumi et al.; “Androstenedione induces abnormalities in morphology and function of developing oocytes, which impairs oocyte meiotic competence”; Journal of Fertility and Sterility; (Feb. 2012); pp. 469-476; vol. 97(2); <doi: 10.1016/j.fertnstert.2011.11.040 >. |
| Tauber et al.; “Absolute bioavailability of testosterone after oral administration of testosterone-undecanoate and testosterone”; European Journal of Drug Metabolism and Pharmacokinetics; (1986); pp. 145-149; vol. 11(2); [Sourcelink] <URL: http://www.ncbi.nlm.nih.gov/pubmed/3770015 >; [Abstract]. |
| Temina et al.; “Diversity of the fatty acids of the Nostoc species and their statistical analysis”; Microbiological Research; (2007); pp. 308-321; Elsevier GmbH. |
| Tenover; “The Androgen-Deficient Aging Male: Current Treatment Options”; Reviews in Urology; (2003); pp. S22-S28; vol. 5, Suppl. 1. |
| Testim® Product Label and Medication Guide; (Sep. 2009); Labeler—A-S Medications Solutions LLC; Revised Jun. 2013; 17 pages. |
| Torpac® Inc.; “Capsule Size Chart, Metric Table and English Table”; (2000); 3 pages; Torpac Inc., Fairfield, New Jersey; [Internet] [retrieved on Sep. 2014] [retrieved from <URL: www.torpac.com >]. |
| Treat et al.; “Liposome Encapsulated Doxorubicin preliminary result of Phase I and Phase II Trials”; Liposomes in the Therapy of Infectious Diseases and Cancer; Lopez-Berestein and Fidler (Eds.); (1989); pp. 353-365; Liss, New York. |
| Tso, et al; “Intestinal Absorption and Lymphatic Transport of a High γ-Linolenic Acid Canola Oil in Lymph Fistula Sprague-Dawley Rats”; The Journal of Nutrition; (2002); pp. 218-221; American Society for Nutritional Sciences. |
| Wang, et al; “Long-term testosterone gel (AndroGel®) Treatment Maintains Beneficial Effects on Sexual Function and Mood, Lean and Fat Mass and Bone Mineral Density in Hypogonadal Men”; Journal of Clinical Endocrinology & Metabolism; (2004); pp. 2085-2098; vol. 89. |
| Webster et al.; “Validation of Pharmaceutical Potency Determinations by Quantitative Nuclear Magnetic Resonance Spectrometry”; Journal of Applied Spectroscopy; (May 2010); pp. 537-542; vol. 64(5). |
| Wilson et al.; “The Behaviour of Fats and Oils in the Upper G.I. Tract”; Bulletin Technique Gattefosse; (1997); pp. 13-18; vol. 90. |
| Winne; “Dependence of Intestinal Absorption in Vivo on the Unstirred Layer”; Archives of Pharmacology; (1978); pp. 175-181; vol. 304. |
| Yassin et al.; “Long-acting testosterone undecanoate for parenteral testosterone therapy”; Therapy, Future Drugs; (2006); pp. 709-721; vol. 3(6). |
| Yin et al., “Dietary Fat Modulates the Testosterone Pharmacokinetics of a New Self-Emulsifying Formulation of Oral Testosterone Undecanoate in Hypogonadal Men”; Journal of Andrology; (Nov./Dec. 2012); pp. 1282-1290; vol. 33(6). |
| Yin et al.; “Reexamination of Pharmacokinetics of Oral Testosterone Undecanoate in Hypogonadal Men with a New Self-Emulsifying Formulation”; Journal of Andrology; (2012); pp. 190-201; vol. 33(2). |
| Zhi et al.;“Effects of dietary fat on drug absorption”; Clinical Pharmacology & Therapeutics; (Nov. 1995); pp. 487-491; vol. 58(5). |
| Andriol® Testocaps®; “Testosterone Undecanoate;” Consumer Medicine Information; [Insert]; (Jul. 2011); 3 pages. |
| Somsen et al.; “Coupling of LC and FT-IR: Impurity Profiling of Testosterone Undecanoate;” Applied Spectroscopy; 46; 10; 1992, pp. 1514-1519. |
| Number | Date | Country | |
|---|---|---|---|
| 20200222425 A1 | Jul 2020 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62175931 | Jun 2015 | US | |
| 62253292 | Nov 2015 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 15861492 | Jan 2018 | US |
| Child | 16726572 | US | |
| Parent | 15183691 | Jun 2016 | US |
| Child | 15861492 | US |
